



ISPOR 20th Annual
International Meeting
May 16-20, 2015
Philadelphia Marriott Downtown
Philadelphia, PA, USA



Research Poster Presentations – Session I

Monday, May 18, 2015

8:30AM-2:15PM

Poster Author Discussion Hour:

1:15PM-2:15PM

Research Poster Presentations – Session I includes the following topics

PRM – RESEARCH ON METHODS

Rows A- I

PMD – MEDICAL DEVICE/DIAGNOSTICS

Rows I-N

PDB – DIABETES/ENDOCRINE DISORDERS **Rows N-X**

A1 Location of the poster in the poster hall – please refer to last page for a floor plan

pgA10 Location of the abstract as published in *Value in Health* Volume 18, Issue 3

RESEARCH POSTER PRESENTATIONS - SESSION I

RESEARCH ON METHODS STUDIES

RESEARCH ON METHODS - Clinical Outcomes Methods

- PRM1 A1 pgA10 DEVELOPMENT AND VALIDATION OF A U.S. ADMINISTRATIVE CLAIMS-BASED ALGORITHM TO CLASSIFY PATIENTS WITH TYPE 2 DIABETES MELLITUS INTO RENAL IMPAIRMENT STAGES**
Johnston S¹, Sheehan J², Riehle E¹, Cappell KA³, Varker H¹, Anzalone D⁴, Ghannam A², Kalsekar I^{4,1}, Truven Health Analytics, Bethesda, MD, USA, ²AstraZeneca, Fort Washington, PA, USA, ³Truven Health Analytics, Ann Arbor, MI, USA, ⁴AstraZeneca, Wilmington, DE, USA
- PRM2 A2 pgA10 COMPARISON OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION AND CHRONIC CONSTIPATION PATIENT IDENTIFICATION UTILIZING ADMINISTRATIVE CLAIMS-BASED ALGORITHMS, MODIFIED ROME III DIAGNOSTIC CRITERIA, AND PATIENT-REPORTED PHYSICIAN DIAGNOSES**
Buono JL¹, Stephenson JJ², Spalding WM³, Cai Q², Tan H², Carson RT¹, Doshi JA^{4,1}, Forest Research Institute, Inc., a subsidiary of Actavis plc, Jersey City, NJ, USA, ²HealthCore Inc., Wilmington, DE, USA, ³Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA, ⁴University of Pennsylvania, Philadelphia, PA, USA
- PRM3 A3 pgA10 PSYCHOMETRIC VALIDATION OF PERFORMANCE OUTCOMES (PERFOS) FOR USE WITH HIP FRACTURE (HF) POPULATIONS**
Gentile B¹, Ballinger RS², Doll HA², Naegeli A³, **Bush EN^{3,1}**, ICON, San Francisco, CA, USA, ²ICON, Oxford, UK, ³Eli Lilly, Indianapolis, IN, USA
- PRM4 A4 pgA10 GETTING THE FULL PICTURE: THE IMPORTANCE OF EXTRAPOLATING BEYOND THE DATA**
Al-Mutairi R, Rittenhouse B, MCPHS University, Boston, MA, USA
- PRM5 A5 pgA11 COMPARING DIAGNOSIS-BASED AND PRESCRIPTION-BASED COMORBIDITY MEASURES FOR PREDICTING HEALTH SERVICE UTILIZATION AND COSTS**
Gangan N, Banahan III B, University of Mississippi, University, MS, USA
- PRM6 A6 pgA11 MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC)**
Tremblay G¹, Holbrook T², Milligan G², Pelletier C^{1,1}, Eisai, Woodcliff Lake, NJ, USA, ²Adelphi Real World, Manchester, UK
- PRM7 A7 pgA11 PROSPECTIVE BENEFIT-RISK MONITORING OF NEW DRUGS FOR RAPID ASSESSMENT OF NET FAVORABILITY IN ELECTRONIC HEALTHCARE DATA**
Gagne JJ¹, Bykov K², **Najafzadeh M¹**, Choudhry NK¹, Martin DP³, Kahler K³, Rogers JR², Schneeweiss S^{1,1}, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, ²Brigham and Women's Hospital, Boston, MA, USA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- PRM8 A8 pgA11 QT PROLONGATION IDENTIFICATION IN RETROSPECTIVE STUDIES**
Ye Y, Caffrey AR, University of Rhode Island, Kingston, RI, USA
- PRM9 A9 pgA11 COMPARISON OF BENEFIT-RISK ASSESSMENT METHODS FOR PROSPECTIVE MONITORING OF NEWLY MARKETED DRUGS: A SIMULATION STUDY**
Gagne JJ¹, **Najafzadeh M¹**, Choudhry NK¹, Bykov K², Kahler K³, Martin DP³, Rogers JR², Schneeweiss S^{1,1}, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, ²Brigham and Women's Hospital, Boston, MA, USA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- PRM10 A10 pgA11 USAGE OF PROPENSITY SCORE, INSTRUMENTAL VARIABLE, OR MACHINE LEARNING FOR REAL WORLD DATA ANALYSIS**
Choi S, PAREXEL International, Billerica, MA, USA
- PRM11 A11 pgA12 EVALUATING CONTENT VALIDITY OF PERFORMANCE OUTCOMES (PERFOS): ESTABLISHING THE PATIENT-RELEVANCE OF THREE PERFOS IN ELECTIVE TOTAL HIP REPLACEMENT (ETHR)**
Ballinger RS¹, Kerr C¹, Bush EN^{2,1}, ICON, Oxford, UK, ²Eli Lilly, Indianapolis, IN, USA
- PRM12 A12 pgA12 CLINICAL TRIALS REGISTRIES FOR SYSTEMATIC REVIEWS – AN ALTERNATIVE SOURCE FOR UNPUBLISHED DATA**
Halfpenny NJ, Thompson JC, Quigley JM, Scott DA, ICON Health Economics, Oxford, UK
- PRM13 A13 pgA12 DATA EXTRACTION FOR SYSTEMATIC REVIEW – WHERE TO LOOK FOR DATA OUTSIDE THE PRIMARY PUBLICATION**
Quigley JM, Halfpenny NJ, Thompson JC, Scott DA, ICON Health Economics, Oxford, UK
- PRM15 A14 pgA12 INVESTIGATION OF RELATIONSHIPS BETWEEN BIOMARKERS OF POTENTIAL HARM AND CIGARETTE SMOKING MEASURES AMONG CURRENT, PAST, AND NON-SMOKERS BASED ON NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2007-2012**
Saxena K¹, Liang Q², Muhammad-Kah R², Sarkar M^{2,1}, Virginia Commonwealth University, Richmond, VA, USA, ²Altria Client Services Inc, Richmond, VA, USA
- PRM16 A15 pgA12 COMBINING MCDA WITH ADVANCED STATISTICS TO TACKLE CHALLENGES OF DATA AND JUDGMENT UNCERTAINTY: CASE STUDY OF SAFETY ASSESSMENTS**
Goetghebeur MM¹, Wagner M², Nikodem M³, Zyla A³, Micallef A⁴, Amzal B^{5,1}, LASER Analytica & University of

Montreal, Montreal, QC, Canada, ²LASER Analytica, Montreal, QC, Canada, ³LASER Analytica, Krakow, Poland, ⁴MerckSerono SA, Eysins, Switzerland, ⁵LASER Analytica, London, UK

- PRM17 A16 pgA13 **LONGITUDINAL AND CROSS SECTIONAL ASSESSMENTS OF HEALTH UTILITY IN ADULTS WITH HIV/AIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Tran B, Hanoi Medical University, Hanoi, Vietnam
- PRM18 A17 pgA13 **IMPROVING PARAMETER ESTIMATION FOR A DECISION-ANALYTIC MARKOV MODEL TO EVALUATE THE USE OF NOVEL BIOMARKER LED STRATEGIES FOR PREVENTION OF CARDIOVASCULAR DISEASE**
Lamrock F¹, Cairns K¹, Kee F¹, Conrads-Frank A², Schnell-Inderst P², Salomaa V³, Blankenberg S⁴, Zeller T⁴, Saarela O⁵, Kuulasmaa K³, Kühne F², Siebert U², ¹Queen's University Belfast, Belfast, UK, ²UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, ³THL - National Institute for Health and Welfare, Helsinki, Finland, ⁴University Health Center Hamburg, Hamburg, Germany, ⁵McGill University, Montreal, QC, Canada
- PRM19 A18 pgA13 **DO DIFFERENT MODELING TECHNIQUES CHANGE RANKINGS OF HOSPITAL PERFORMANCE? : MULTILEVEL MODELING VS. STANDARD LOGISTIC REGRESSION**
Yucel A, Ferries EA, Sharma M, Johnson M, Aparasu R, University of Houston, Houston, TX, USA
- PRM20 A19 pgA13 **COMPARING THE PREDICTIVE PERFORMANCE OF TWO VARIANTS OF THE ELIXHAUSER COMORBIDITY MEASURES FOR ALL-CAUSE IN-HOSPITAL MORTALITY IN A LARGE MULTI-PAYER U.S. ADMINISTRATIVE DATABASE**
Fortin Y¹, Crispo J¹, Emons MF², Mattison DR³, Krewski D¹, ¹University of Ottawa, Ottawa, ON, Canada, ²Cerner Corporation, Culver City, CA, USA, ³Risk Sciences International, Ottawa, ON, Canada
- PRM21 A20 pgA13 **STATISTICAL IDENTIFICATION OF PATIENT SELECTION BIAS IN RETROSPECTIVE CHART REVIEWS**
Signorovitch JE¹, Reichmann WM¹, Li N¹, Liu Z², Hao Y², Perez JR², ¹Analysis Group, Inc., Boston, MA, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- PRM22 A21 pgA14 **METASTATIC-FREE SURVIVAL AND OVERALL SURVIVAL IN PROSTATE CANCER**
Li T¹, Thompson M², Tran D², ¹Janssen Global Services, Raritan, NJ, USA, ²Cornerstone Research Group, Burlington, ON, Canada

RESEARCH ON METHODS - Cost Methods

- PRM23 B1 pgA14 **CONTRASTING COST-EFFECTIVENESS RESULTS DERIVED FROM CONTEMPORARY SETS OF ALTERNATIVE RISK EQUATIONS IN TYPE 2 DIABETES**
Foos V¹, Lamotte M², McEwan P³, ¹IMS Health, Basel, Switzerland, ²IMS Health Consulting, Brussels, Belgium, ³Health Economics and Outcomes Research Ltd, Monmouth, UK
- PRM24 B2 pgA14 **COST-BENEFIT ANALYSIS OF WHOLE BODY BONE SCINTIGRAPHY IN THE PRE-TRANSPLANT ASSESSMENT OF ADULT PATIENTS, BEARERS OF HEPATOCELLULAR CARCINOMA, IN A LIVER TRANSPLANT WAITING LIST, FROM DEAD DONORS, IN A REFERENCE HOSPITAL IN THE SOUTH OF BRAZIL**
Balbinotto G¹, Brandão A², Rodriguez S², ¹Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²UFCSA, PORTO ALEGRE, Brazil
- PRM25 B3 pgA14 **COST-UTILITY EVALUATION OF CONTINUING EDUCATION FOR THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS USERS IN PERNAMBUCO – BRAZIL**
Aquino CM¹, Lima RC², Bezerra AF², Sousa IM³, Cesse EÁ³, Carvalho EM², Fontbonne A⁴, ¹Federal University of Pernambuco, Recife, Brazil, ²Federal University of Pernambuco, RECIFE, Brazil, ³Oswaldo Cruz Foundation - Fiocruz, Recife, Brazil, ⁴Institut de Recherche pour le Développement, Marseille, France
- PRM26 B4 pgA14 **MODELS USED IN ECONOMIC ANALYSES OF TICAGRELOR AND PRASUGREL FOR ACUTE CORONARY SYNDROMES: A STRUCTURED REVIEW**
Law EH, Sharma D, Pickard S, University of Illinois at Chicago, Chicago, IL, USA
- PRM27 B5 pgA14 **REVIEW OF COST-EFFECTIVENESS ANALYSES OF VARICELLA VACCINATION: WHICH MODEL STRUCTURE ASSUMPTIONS AND INPUT PARAMETERS MATTER?**
Talbird SE¹, Mauskopf JA¹, Yang HK², ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Merck & Co., Inc., West Point, PA, USA
- PRM28 B6 pgA15 **IMPLICATIONS OF THE INTER-RELATEDNESS OF THE PROPORTIONAL AND ABSOLUTE QALY SHORTFALL MEASUREMENTS FOR DISEASE BURDEN**
Kusel J, Beale RC, Maruszczak M, Costello Medical Consulting Ltd., Cambridge, UK
- PRM29 B7 pgA15 **EXPLORING POTENTIAL DRIVERS OF THE SYSTEMATIC OVERUSE OF HEALTHCARE IN THE UNITED STATES USING THE JOHNS HOPKINS OVERUSE INDEX (JHOI)**
Bridges JF¹, **Zhou M**¹, Segal J², ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ²Johns Hopkins University, Baltimore, MD, USA
- PRM30 B8 pgA15 **SHOULD DECISION MAKERS EMBRACE NON-CONSTANT DISCOUNTING?**
Paulden M, McCabe C, University of Alberta, Edmonton, AB, Canada
- PRM31 B9 pgA15 **EXPLICATIVE MODEL OF THE HEALTH EXPENDITURE FOR CONTRIBUTIVE HEALTH SUBSYSTEM POPULATION IN COLOMBIA**

Romero M¹, Marrugo R², Acero G³, Quinche G⁴, Grosso G⁵, Moreno Y⁶, Lee J⁴, Reinales J⁴, Vivas D⁷, ¹Salutia Foundation, Bogota, Colombia, ²Salutia's Foundation- Research center in economy, management and health technologies., Bogota, Colombia, ³Salutia Foundation- Research center in economy, management and health technologies., Bogota, Colombia, ⁴Coomeva Group, Cali, Colombia, ⁵Group SaludCoop, Bogotá, Colombia, ⁶Saludcoop group, Bogotá, Colombia, ⁷universidad Politécnica de Valencia, Valencia, Saipan

PRM32 B10 pgA15 SUGGESTION OF NEW METHODS TO CALCULATE CONFIDENCE INTERVAL FOR INCREMENTAL COST-EFFECTIVENESS RATIO WHICH SOLVE THE ISSUES WITH CONVENTIONAL METHOD

Aranishi T, Ikeda S, International University of Health and Welfare, Ohtawara City, Japan

PRM33 B11 pgA16 METHODOLOGY USING PHARMACY AND MEDICAL CLAIMS DATA TO EVALUATE REAL-WORLD OUTCOMES AND COSTS OF IVF TREATMENT IN THE US

Corvino FA¹, Surinach A¹, Locklear JC², **Howe AM**², Hayward B², Mahony MC², ¹Genesis Research, LLC, Hoboken, NJ, USA, ²EMD Serono, Inc., Rockland, MA, USA

PRM34 B12 pgA16 A COST ANALYSIS OF KIDNEY THERAPY OPTIONS

Younis M¹, Forgione D², **Alkatib A**³, Jabr S⁴, Hartmann M⁵, Kisa A⁶, ¹Jackson State University, New Orleans, LA, USA, ²UTSA, San Antonio, Palestine, ³Al-watani Hospital, Ramallah, Palestine, ⁴Ministry of Health, Ramallah, Palestine, ⁵Friedrich Schiller University of Jena, Jena, Germany, ⁶Zirve University, Gaziantep, Turkey

PRM35 B13 pgA16 ASSESSING THE INCREMENTAL PREDICTIVE VALUE OF HEALTHCARE UTILIZATION PATHWAYS IN RISK PREDICTION MODELING

Kuwornu JP¹, Lix L¹, Quail J², Wang E², Osman M², Teare G², ¹University of Manitoba, Winnipeg, MB, Canada, ²Saskatchewan Health Quality Council, Saskatoon, SK, Canada

PRM36 B14 pgA16 NON-DISCRETIONARY INPUTS ARE IMPORTANT FACTORS IN HOSPITAL EFFICIENCY STUDIES AND POLICY EVALUATION

Pasupathy K, Sir M, Mayo Clinic, Rochester, MN, USA

PRM37 B15 pgA16 IMPACT OF SINGLE RISK FACTOR CHANGES ON LONG-TERM OUTCOMES AND COST IN A TYPE 2 DIABETES MODELING STUDY CONTRASTING PROJECTIONS WITH UKPDS68, SWEDISH NATIONAL DIABETES REGISTRY AND THE ADVANCE RISK EQUATIONS

McEwan P¹, Lamotte M², Foes V³, ¹Health Economics and Outcomes Research Ltd, Monmouth, UK, ²IMS Health Consulting, Brussels, Belgium, ³IMS Health, Basel, Switzerland

PRM38 B16 pgA16 THE COST OF DRUG-RELATED MORBIDITY THAT LEAD TO EMERGENCY VISITS IN A BRAZILIAN HOSPITAL

Freitas G¹, **Balbinotto G**², Hughes D³, Heineck I¹, ¹UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, PORTO ALEGRE, Brazil, ²Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Bangor University, Bangor, UK

RESEARCH ON METHODS - Databases & Management Methods

PRM39 B17 pgA17 IS THE PREVALENCE OF ALZHEIMER'S DISEASE UNDERESTIMATED? COMPARISONS AND CONTRASTS OF DIFFERENT APPROACHES IN ESTIMATING ALZHEIMER'S DISEASE

Yuan J, Lu K, University of South Carolina, Columbia, SC, USA

PRM40 B18 pgA17 UNIFIED DATABASE CREATION APPLIED TO PUBLIC BRAZILIAN HEALTH INFORMATION SYSTEMS FROM THE HOSPITAL, OUTPATIENT AND MORTALITY INFORMATION SYSTEMS

Pereira RG¹, Leal GS², Silva LV³, Andrade EI¹, Acurcio Fd², Cherchiglia ML¹, Guerra Junior AA², ¹Federal University of Minas Gerais, Belo Horizonte, Brazil, ²College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, ³Faculdade Promove, Belo Horizonte, Brazil

PRM41 B19 pgA17 VALIDITY OF MEDICAID ANALYTIC EXTRACT (MAX)-2009, OUTPATIENT (OT) AND PROVIDER CHARACTERISTICS (PC) DATA FOR USE IN MENTAL HEALTH RESEARCH

Medhekar R, Chen H, University of Houston, Houston, TX, USA

PRM43 B20 pgA17 DEVELOPMENT OF A DATABASE OF PUBLISHED REGULATORY RECOMMENDATIONS CONCERNING THE USE OF CLINICAL OUTCOME ASSESSMENT (COAS) IN DRUG DEVELOPMENT: OUTCOMES INSITE

Perret C¹, Roborel de Climens A², ¹Mapi Research Trust, Lyon, France, ²Mapi, Lyon, France

PRM44 B21 pgA17 A VIRTUAL DATABASE TO MEASURE COSTS ASSOCIATED WITH COMORBIDITIES AMONG PATIENTS WITH CHRONIC HCV

Kawabata H¹, Behl A¹, Hines P¹, Liu T¹, Sill B¹, Hede S¹, Gorsh B¹, Moorthy V², ¹Bristol-Myers Squibb, Plainsboro, NJ, USA, ²Mu Sigma, Northbrook, IL, USA

PRM45 C1 pgA18 BIG DATA IN EMERGENCY DEPARTMENT CARE DELIVERY: BENEFITS OF RADIO FREQUENCY IDENTIFICATION

Benkhadra K, Sir M, Nestler D, Hellmich T, **Pasupathy K**, Mayo Clinic, Rochester, MN, USA

PRM46 C2 pgA18 WHY PEER-REVIEW JOURNALS REJECT REAL-WORLD AND HEALTH-ECONOMIC PAPERS

Hartog TE¹, **Peters K**², Diamond M¹, Nuottamo N¹, ¹Excerpta Medica, Amsterdam, The Netherlands, ²Excerpta Medica, London, UK

PRM47 C3 pgA18 UTILIZING ELECTRONIC MEDICAL RECORD NETWORKS FOR IDENTIFYING PATIENTS FOR CLINICAL TRIAL RECRUITMENT

- SPENCER J**, Wilson A, Bailey N, Longson MS, Kamau A, Anolinx, Murray, UT, USA
- PRM48 C4 pgA18 **COMPARATIVE LANDSCAPE ASSESSMENT OF US HEALTHCARE DATABASES FOR USE IN HEALTH ECONOMICS MODELING**
Wehler EA¹, Donga P¹, Munakata J², IMS Health, Plymouth Meeting, PA, USA, ²IMS Health, San Francisco, CA, USA
- PRM49 C5 pgA18 **VALIDITY AND LIMITATIONS OF THE LONGITUDINAL PATIENT DATABASE FRANCE FOR USE IN PHARMACOEPIDEMOLOGICAL AND PHARMACOECONOMICS STUDIES**
Jouaville SL, Miotti H, COFFIN G, SARFATI B, Meihoc A, Cededim Strategic Data, Boulogne-Billancourt, France
- PRM50 C6 pgA18 **LACK OF ADHERENCE TO IMMUNOSUPPRESSIVE TREATMENT IN KIDNEY TRANSPLANT PATIENTS: COMPUTER ASSISTED QUALITATIVE DATA ANALYSIS (CAQDAS) OF AN EXPERT PANEL**
Callejo D¹, Rodríguez-Aguilella A¹, Fernández-Ortiz L¹, González E², Toledo A², Rebollo P¹, Muduma G³, Laser Analytica, Oviedo, Spain, ²Astellas Pharma SA, Madrid, Spain, ³Astellas Pharma EMEA, Chertsey, UK

RESEARCH ON METHODS - Modeling Methods

- PRM51 C7 pgA19 **REPLICATION OF A PUBLISHED MARKOV CHRONIC MIGRAINE COST-EFFECTIVENESS ANALYSIS MODEL FOR PURPOSES OF EARLY PHASE ADAPTATION AND EXPANSION**
Smolen LJ, Klein TM, **Kelton K**, Medical Decision Modeling Inc., Indianapolis, IN, USA
- PRM52 C8 pgA19 **RECONSTRUCTION OF INDIVIDUAL PATIENT DATA BASED ON PUBLISHED KAPLAN-MEIER CURVES: CASE OF REGORAFENIB FOR COLORECTAL CANCER**
Ali AA, Adunlin G, Xiao H, Diaby V, Florida A & M University, Tallahassee, FL, USA
- PRM53 C9 pgA19 **CHOICE OF DISTRIBUTIONAL ASSUMPTIONS IN META-ANALYSIS FOR THE EVALUATION OF SURROGATE ENDPOINTS**
Spata E, Abrams KR, Thompson J, Bujkiewicz S, University of Leicester, Leicester, UK
- PRM54 C10 pgA19 **UNIVERSAL CLOPIDOGREL VERSUS CYP2C19-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME - A COST-EFFECTIVENESS ANALYSIS**
Jiang M, You J, The Chinese University of Hong Kong, Shatin, Hong Kong
- PRM55 C11 pgA19 **JOINT ESTIMATION OF MARKOV CHAIN TRANSITION PROBABILITIES USING SURVIVAL MODELS AND CONSTRAINED OPTIMIZATION: A CASE STUDY ON DIABETES AND MORTALITY AND THEIR ASSOCIATION WITH BODY MASS INDEX, AGE, AND GENDER**
Wu S¹, Li J¹, Carlsson NP², Leung MY², Colditz GA², Chang S², ¹Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO, USA, ²Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA
- PRM56 C12 pgA20 **TREE-BASED CLAIMS ALGORITHM FOR MEASURING PRE-TREATMENT QUALITY OF CARE IN MEDICARE DISABLED HEPATITIS C PATIENTS**
Chirikov VV¹, Shaya FT¹, Onukwughu E¹, Mullins CD¹, dosReis S¹, Howell CD², ¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Howard University College of Medicine, Washington, MD, USA
- PRM57 C13 pgA20 **COST-EFFECTIVENESS EVALUATION OF GENOTYPE-GUIDED ANTIPLATELET THERAPY VERSUS UNIVERSAL NEW ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME**
Jiang M, You J, The Chinese University of Hong Kong, Shatin, Hong Kong
- PRM59 C14 pgA20 **REAL-WORLD DATA UTILITY FOR HEALTH ECONOMIC MODELING: AN ASSESSMENT OF CURRENT DATA SOURCES**
Gavaghan M¹, Armstrong S², Taggart C², Garfield S², ¹GfK, Wayland, MA, USA, ²GfK Custom Research, Wayland, MA, USA
- PRM60 C15 pgA20 **A NEW COST-EFFECTIVENESS FRAMEWORK FOR MODELING PSORIASIS TREATMENTS**
Graham C¹, Mollon P², Miles L¹, McBride D¹, ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Novartis Pharma AG, Basel, Switzerland
- PRM61 C16 pgA20 **NATIONAL BURDEN OF HOSPITALIZATIONS FOR NECROTIZING ENTEROCOLITIS: RESULTS FROM THE 2009 KID'S INPATINET DATABASE**
Jiao X, Han X, University of Southern California, Los Angeles, CA, USA
- PRM62 D1 pgA20 **REDUCTION OF INFLUENZA DISEASE COST WITH SUBOPTIMAL VACCINATION**
Bailey N, Li Y, Wilson A, Anolinx, Murray, UT, USA
- PRM63 D2 pgA21 **FEASIBILITY AND ACCEPTABILITY OF MINIMAL MODELING VALUE OF INFORMATION ANALYSES FOR REAL-TIME PRIORITIZATION DECISIONS WITHIN A LARGE CANCER CLINICAL TRIALS COOPERATIVE GROUP**
Bennette CS¹, Veenstra DL¹, Basu A¹, Ramsey S², Carlson JJ¹, ¹University of Washington, Seattle, WA, USA, ²Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- PRM64 D3 pgA21 **ALTERNATIVE METHODS FOR GENERATING ARBITRARY MARGINAL DISTRIBUTIONS AND THE IMPLICATIONS FOR SIMULATION OUTCOMES**
Zhuo JX, Merck, North Wales, PA, USA
- PRM65 D4 pgA21 **AN EVALUATION OF COMPETING MODELS FOR PREDICTING CV EVENT RATES FROM LDL-C LEVELS**

IN SECONDARY PREVENTION

Conner C, Health Strategy, LLC, Remdond, WA, USA

- PRM66 D5 pgA21 **THE WORLD HEALTH ORGANIZATION AND UNIVERSAL DIAGNOSTIC TESTING FOR SUSPECTED MALARIA IN CHILDREN: IS THE NEW POLICY COST-EFFECTIVE AND AFFORDABLE FOR SUB-SAHARAN AFRICA?**
Phillips V, Emory University, Atlanta, GA, USA
- PRM67 D6 pgA21 **WHOLE-DISEASE MODEL APPROACH: METHODOLOGIES AND CHALLENGES IN COMMUNICATING THE ECONOMIC BURDEN OF RARE DISEASES**
Shah A, Proach J, Market Access Solutions LLC, Raritan, NJ, USA
- PRM68 D7 pgA22 **CALIBRATING AN INTEGRATED PHARMACOECONOMIC-PHARMACOMETRIC MODEL OF COPD TREATMENT: WHAT A DIFFERENCE THE VARIANCE MAKES**
Slejko JF¹, Willke RJ²,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Pfizer, Inc., New York, NY, USA
- PRM69 D8 pgA22 **INFORMING UNCERTAIN MODEL PARAMETERS THROUGH MODEL CALIBRATION: HUMAN PAPILOMAVIRUS (HPV) MODEL CASE STUDY**
Minayev P¹, Dasbach EJ², Pillsbury M²,¹MSD IT Global Innovation Network @ Prague, Prague, Czech Republic, ²Merck & Co. Inc., North Wales, PA, USA
- PRM70 D9 pgA22 **PRACTICAL ISSUES IN DEVELOPING ECONOMIC MODELS FOR TARGETED TREATMENTS**
Wlodarczyk J¹, Kemp D¹, Leadbitter S²,¹John Wlodarczyk Consulting Services, New Lambton, Australia, ²AstraZeneca, North Ryde, Australia
- PRM71 D10 pgA22 **PROGRESSION OF VISION LOSS IN PATIENTS WITH GEOGRAPHIC ATROPHY- A DISEASE MODEL**
Arjunji R¹, Wang F¹, Gutierrez B¹, Bhattacharyya A¹, Alfonso R¹, Williams R¹, Dabbous O²,¹GSK, King of Prussia, PA, USA, ²GlaxoSmithKline, King of Prussia, PA, USA
- PRM72 D11 pgA22 **REVIEW OF METHODOLOGICAL APPROACHES TO GENERATE PROPENSITY SCORES IN MULTILEVEL DATA**
Sarangpur S¹, Jamotte A², Thokagevistik K¹, Sherman S¹,¹Creativ-Ceutical, Chicago, IL, USA, ²Creativ-Ceutical, Paris, IL, USA
- PRM73 D12 pgA22 **CONTRASTING THE RELATIVE RISK REDUCTION OF CARDIOVASCULAR EVENTS IN THE CORE DIABETES MODEL ASSOCIATED WITH SINGLE RISK FACTOR CHANGES ACROSS ALTERNATIVE RISK ENGINES: UKPDS68, UKPDS82 AND SWEDISH NATIONAL DIABETES REGISTRY EQUATIONS**
Foos V¹, Lamotte M², McEwan P³,¹IMS Health, Basel, Switzerland, ²IMS Health Consulting, Brussels, Belgium, ³Health Economics and Outcomes Research Ltd, Monmouth, UK
- PRM74 D13 pgA23 **ASSESSING THE RELATIVE CONTRIBUTION TO CHANGES IN QUALITY-ADJUSTED LIFE EXPECTANCY ASSOCIATED WITH HBA1C, WEIGHT AND HYPOGLYCAEMIA ACROSS MULTIPLE RISK EQUATIONS WITH THE CORE DIABETES MODEL (CDM)**
McEwan P¹, Evans M², Lamotte M³, Foos V⁴,¹Health Economics and Outcomes Research Ltd, Monmouth, UK, ²University Hospital Llandough, Cardiff, UK, ³IMS Health Consulting, Brussels, Belgium, ⁴IMS Health, Basel, Switzerland
- PRM75 D14 pgA23 **META-ANALYSIS FOR THE EVALUATION OF MULTIPLE SURROGATE ENDPOINTS**
Bujkiewicz S, Spata E, Thompson JR, Abrams K, University of Leicester, Leicester, UK
- PRM76 D15 pgA23 **ASSESSING THE VARIABLES AFFECTING THE COMPLETION OF A COMPLIANCE MONITORING PROGRAM (CMP) FOR NURSES UNDERGOING SUBSTANCE ABUSE TREATMENT**
Pandya SA¹, Moes S², Peterson AM³,¹University of the Sciences, Philadelphia, PA, USA, ²Livengrin Foundation, Inc, Bensalem, PA, USA, ³University of the Sciences in Philadelphia, Philadelphia, PA, USA
- PRM77 D16 pgA23 **A BAYESIAN FRAMEWORK TO ESTIMATE THE COST OF CARE FOR RENAL DISEASE PATIENTS WITH AND WITHOUT A USUAL SOURCE OF CARE PROVIDER**
Zanwar P¹, Parthasarathy M², Damien P³,¹University of Houston Clear Lake, Houston, TX, USA, ²Saaraa Medical Solutions Pvt Ltd, Whitehouse Station, NJ, USA, ³University of Texas at Austin, Austin, TX, USA
- PRM78 E1 pgA23 **THE USE OF BOOTSTRAP MODEL AVERAGING WHEN ESTIMATING SURVIVAL CURVES**
Parker C¹, Hawkins N²,¹ICON Health Economics, Oxford, UK, ²London School of Hygiene & Tropical Medicine, London, UK

RESEARCH ON METHODS - Patient-Reported Outcomes Studies

- PRM79 E2 pgA23 **DEVELOPMENT AND VALIDATION OF THE HEMOPHILIA-SPECIFIC BURDEN SCALE FOR CAREGIVERS OF CHILDREN WITH HEMOPHILIA IN THE US – THE HEMOPHILIA ASSOCIATED CAREGIVER BURDEN SCALE (HEMOCABTM)**
von Mackensen S¹, Wisniewski T², Urgo J³, Boggio L³,¹University Medical Center, Hamburg, Germany, ²NOVO Nordisk, Plainsboro, NJ, USA, ³RUSH University Medical Centre, Chicago, IL, USA
- PRM81 E3 pgA24 **USING THE CLINICAL SUMMARY SCORE FROM THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE AS AN ENDPOINT IN CLINICAL TRIALS: PSYCHOMETRIC SUPPORT**
Gwaltney C¹, Tiplady B¹, Deschaseaux C²,¹ERT, Pittsburgh, PA, USA, ²Novartis Pharma AG, Basel, Switzerland

- PRM82 E4 pgA24 VALIDATION AND U.S. POPULATION NORMS OF HEALTH-RELATED PRODUCTIVITY QUESTIONNAIRE**
Tundia N¹, Hass S², Fuldeore M¹, Wang LL³, Cavanaugh T³, Boone J³, Heaton P³,¹AbbVie Inc., North Chicago, IL, USA, ²Genzyme, Cambridge, IL, USA, ³University of Cincinnati, Cincinnati, OH, USA
- PRM83 E5 pgA24 MEASURING UPPER LIMB FUNCTION IN MULTIPLE SCLEROSIS: ENHANCING THE ABILHAND'S PERFORMANCE**
Cano S¹, Cleanthous S², Marquis P³, Hobart J⁴, Naoshy S⁵, Mikol D⁵, Petrillo J⁵, Steiner D⁵, Chen Y⁵, Watson C⁵,¹Modus Outcomes LLC, Stotfold, UK, ²Modus Outcomes LLC, London, UK, ³Modus Outcomes LLC, Newton, MA, USA, ⁴Plymouth University, Plymouth, Devon, UK, ⁵Biogen Idec, Cambridge, MA, USA
- PRM84 E6 pgA24 VALIDATION OF THE DEPRESSION AND FAMILY FUNCTIONING SCALE (DFFS)**
Francois C¹, Danchenko N², Williams V³, Nelsen L³, Williams NJ³, Yarr S⁴, DiBenedetti DB³, Lancon C⁵,¹Lundbeck LLC, Deerfield, IL, USA, ²Lundbeck S.A.S. Paris Fr, EU, Paris, France, ³RTI Health Solutions, Research Triangle Park, NC, USA, ⁴The Pavilion, Manchester, UK, ⁵Hospital Sainte-Marguerite, Marseille, France
- PRM85 E7 pgA24 DOES DIFFERENTIAL FRAMING OF OPT-OUT ALTERNATIVES IN DISCRETE CHOICE EXPERIMENTS (DCES) MATTER? COMPARISON OF RANDOM UTILITY MAXIMIZATION (RUM) AND RANDOM REGRET MINIMIZATION (RRM) MODELS**
Chaugule S¹, Hay JW¹, Young G², Martin OA³, Drabo EF¹,¹University of Southern California, Los Angeles, CA, USA, ²Children's Hospital Los Angeles, Los Angeles, CA, USA, ³Barcelona GSE, Barcelona, Spain
- PRM87 E8 pgA25 THE INFLUENCE OF PAIN MANAGEMENT TREATMENT ATTRIBUTES ON CLINICAL DECISION MAKING IN POSTOPERATIVE PAIN MANAGEMENT**
Abraham J¹, Lozano-Ortega G², Ogden K³, Jones J⁴,¹The Medicines Company, Waltham, MA, USA, ²ICON, Vancouver, BC, Canada, ³ICON, San Francisco, CA, USA, ⁴The Medicines Company, Parsippany, NJ, USA
- PRM88 E9 pgA25 DEVELOPMENT OF THE HYPERPHAGIA QUESTIONNAIRE FOR USE IN PRADER-WILLI SYNDROME CLINICAL TRIALS**
Fehnel SE¹, Brown TM¹, Nelson L¹, Chen A², Kim DD², Roof E³, Dykens EM³,¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Zafgen, Inc., Boston, MA, USA, ³Vanderbilt University, Nashville, TN, USA
- PRM89 E10 pgA25 PATIENTS' EXPERIENCES WITH MYCOSIS FUNGOIDES/SÉZARY SYNDROME - CUTANEOUS T-CELL LYMPHOMA (MF/SS-CTCL): EVIDENCE FROM QUALITATIVE RESEARCH OF A PATIENT REPORTED OUTCOME (PRO) MEASURE DEVELOPED ON AN ONLINE RESEARCH PLATFORM**
Towner A¹, Raja P¹, Braverman J¹, Harrington M¹, Simacek K¹, Nagao M², Sepassi M²,¹PatientsLikeMe, Cambridge, MA, USA, ²Actelion Pharmaceuticals US, Inc., South San Francisco, CA, USA
- PRM90 E11 pgA25 CONTENT VALIDITY OF A PATIENT-REPORTED OUTCOME INSTRUMENT FOR PANCREATIC CANCER**
Turner-Bowker DM¹, Paty J², Celeste Elash CA³, Hare T⁴, Leopold L⁴, Cline J³, Ascoytia C⁵,¹Quintiles (work conducted while at ERT, Pittsburgh, PA), Cambridge, MA, USA, ²Quintiles, Hawthorne, NY, USA, ³ERT, Pittsburgh, PA, USA, ⁴Incyte Corporation, Wilmington, DE, USA, ⁵Health Research Associates, Mountlake Terrace, WA, USA
- PRM91 E12 pgA25 DEPRESSION AND QUALITY OF LIFE AMONG INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN NORTH INDIA**
 Negi H¹, **Raval A²**,¹Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, ²West Virginia University, Morgantown, WV, USA
- PRM92 E13 pgA26 MEASURING THE SYMPTOMS AND IMPACTS OF ENDOMETRIOSIS: PSYCHOMETRIC VALIDATION OF THE ENDOMETRIOSIS SYMPTOM DIARY AND ENDOMETRIOSIS IMPACT SCALE**
Gater A¹, Moore A², Coon CD³, Chen WH⁴, Wichmann K⁵, Hartisch C⁵, Filonenko A⁵, Seitz C⁵, Gerlinger C⁵,¹Adelphi Values, Bollington, Cheshire, UK, ²Adelphi Values Ltd, Bollington, Cheshire, UK, ³Adelphi Values, Boston, MA, USA, ⁴RTI Health Solutions, North Potomac, MD, USA, ⁵Bayer Pharma AG, Berlin, Germany
- PRM93 E14 pgA26 WHAT TYPE OF RESPONSE SCALE IS THE MOST RESPONSIVE? A COMPREHENSIVE REVIEW OF RESPONSE SCALE OPTIONS FOR PATIENT-REPORTED OUTCOME MEASURES**
Rudell K¹, Vernon MK², Gries KS³, Safikhani S⁴, DeLozier AM⁵, McQuarrie K⁶, Norquist JM⁷, Coons SJ⁸,¹Pfizer Inc, Tadworth, UK, ²Evidera, London, UK, ³Evidera, Seattle, WA, USA, ⁴Evidera, Bethesda, MA, USA, ⁵Lilly, Indianapolis, IN, USA, ⁶Janssen, Horsham, PA, USA, ⁷Merck & Co Whitehouse Station, Whitehouse Station, NJ, USA, ⁸Critical Path Institute, Tucson, AZ, USA
- PRM94 E15 pgA26 PSYCHOMETRIC VALIDATION OF THE FATIGUE SYMPTOMS AND IMPACTS QUESTIONNAIRE-RELAPSING MULTIPLE SCLEROSIS (FSIQ-RMS™)**
Hudgens S¹, Schüler R², Hunsche E², Leist T³,¹Clinical Outcomes Solutions, Tucson, AZ, USA, ²Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ³Thomas Jefferson University Hospital, Philadelphia, PA, USA
- PRM95 E16 pgA26 FEASIBILITY OF USING THE SF-36 HEALTH SURVEY TO SCREEN FOR RISK OF MAJOR DEPRESSIVE DISORDER**
Bell JA¹, DiBonaventura MD², Witt EA³, Ben-Joseph R¹, Reeve BB⁴,¹Purdue Pharma L.P., Stamford, CT, USA, ²Kantar Health, New York, NY, USA, ³Kantar Health, Princeton, NJ, USA, ⁴University of North Carolina, Chapel Hill, NC, USA
- PRM96 F1 pgA26 EXAMINING THE RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND INCREASING NUMBERS OF DISEASES**

Rand-Hendriksen K¹, Augestad LA¹, Whitehurst DG², Barra M³,¹University of Oslo, Oslo, Norway, ²Simon Fraser University, Burnaby, BC, Canada, ³Akershus University Hospital, Lørenskog, Norway

PRM97 F2 pgA27 **ELICITING PATIENT TREATMENT PREFERENCES: DEVELOPMENT OF A METHODOLOGICAL FRAMEWORK FOR ATTRIBUTE IDENTIFICATION AND VALIDATION FOR DISCRETE CHOICE EXPERIMENTS**

Camelo Castillo W¹, Ross MM¹, Fitz-Randolph M², dosReis S¹,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²PatientsLikeMe, Cambridge, MA, USA

PRM98 F3 pgA27 **PHARMACISTS-LED INTERVENTIONS TO IMPROVE HEALTH-RELATED QUALITY OF LIFE OF PULMONARY TUBERCULOSIS PATIENTS IN PAKISTAN: AN INSIGHT FROM A RANDOMIZED CONTROLLED NON-CLINICAL TRIAL**

Iqbal MS¹, Iqbal MZ², Iqbal MW³, Nasir S⁴, Bahari MB⁵,¹Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, ²Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, ³Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia, ⁴Nishtar Hospital, Multan, Pakistan, ⁵Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia

PRM99 F4 pgA27 **DEVELOPING SF-6D-V2: EXAMINING THE DIMENSIONALITY OF THE SF-36 USING LARGE MULTINATIONAL DATASETS**

Mulhern B¹, Brazier J², Bjorner JB³,¹University of Technology Sydney, Sydney, Australia, ²University of Sheffield, Sheffield, UK, ³Optum PatientInsights, Lincoln, RI, USA

PRM100 F5 pgA27 **DEVELOPMENT AND VALIDATION OF THE PROMIS NETWORK TO EVALUATE PATIENT-REPORTED HEALTH STATUS ASSOCIATED WITH CLOSTRIDIUM DIFFICILE INFECTION**

Desai NS¹, Vuong NN², Bozorgui S³, Goddu S³, Broderick KC¹, Kuo JK⁴, Shah DN⁴, Garey KW⁴,¹Cubist Pharmaceuticals, Lexington, MA, USA, ²University of Houston College of Pharmacy, Houston, TX, USA, ³St. Luke's Episcopal Hospital, Houston, TX, USA, ⁴Department of Clinical Sciences and Administration University of Houston College of Pharmacy, Houston, TX, USA

PRM101 F6 pgA27 **VALIDATION AND VALUATION OF THE PREFERENCE-BASED HEALTHINDEX USING EQ-5D-5L IN THE HONG KONG POPULATION**

Wong EL¹, Yeoh EK¹, Slaap B², Tam WW³, Cheung AW¹, Wong AY¹, Chan DC¹,¹The Chinese University of Hong Kong, Shatin, Hong Kong, ²The EuroQol Group Association, Rotterdam, The Netherlands, ³National University of Singapore, Singapore, Singapore

PRM102 F7 pgA27 **USABILITY TESTING OF THE WEB-BASED VERSIONS OF THE STANDARDISED ASTHMA QUALITY OF LIFE QUESTIONNAIRE FOR 12 YEARS AND OLDER (AQLQ(S)+12) AND THE ASTHMA CONTROL QUESTIONNAIRE (ACQ-6)**

Juniper EF¹, Lambe J², Thomas M³, Arden-Close E³, Grataloup G²,¹McMaster University, Hamilton, ON, Canada, ²Mapi, Lyon, France, ³University of Southampton, Southampton, UK

PRM103 F8 pgA28 **DEVELOPMENT AND CONTENT VALIDITY OF A PEDIATRIC FUNCTIONAL CONSTIPATION DAILY DIARY**

Turner-Bowker DM¹, Lindner E², Mareya S², Losch-Beridon T², Elash CA³, Paty J⁴, Keithly S⁵, Ascoytia C⁵,¹Quintiles (work conducted while at ERT, Pittsburgh, PA), Cambridge, MA, USA, ²Sucampo Pharma Americas LLC, Bethesda, MD, USA, ³ERT, Pittsburgh, PA, USA, ⁴Quintiles, Hawthorne, NY, USA, ⁵Health Research Associates, Mountlake Terrace, WA, USA

PRM104 F9 pgA28 **WHEN THE LITERAL MEANING JUST WON'T DO - CULTURAL ADAPTATION ISSUES RESOLVED DURING THE LINGUISTIC VALIDATION OF A BEHAVIOURAL SCALE**

Williams H, Oke L, Scharf L, Anderson H, Gergovich B, ICON Plc, Oxford, UK

PRM105 F10 pgA28 **MEASUREMENT EQUIVALENCE AND PATIENT PREFERENCE FOR THE SF-36V2 ON A HANDHELD DEVICE AND SMARTPHONE APP**

Khurana L¹, White MK², Bjorner JB², Gary ST¹, Vazquez V¹, Otero A¹, Dallabrida S¹,¹PHT Corporation, Boston, MA, USA, ²Optum PatientInsights, Lincoln, RI, USA

PRM106 F11 pgA28 **DEVELOPMENT AND VALIDATION OF THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR (ACEI) INDUCED ANGIOEDEMA INVESTIGATOR RATING SCALE AND PROPOSED DISCHARGE CRITERIA**

Bonner N¹, Kimura A², Panter C¹, Sinert R³, Moellman JJ⁴, Bernstein JA⁴,¹Adelphi Values Ltd, Bollington, UK, ²Shire HGT, Lexington, MA, USA, ³SUNY - Downstate Medical Centre, Brooklyn, NY, USA, ⁴University of Cincinnati, Cincinnati, OH, USA

PRM107 F12 pgA28 **DEVELOPMENT OF A DISEASE MODEL FOR SPORADIC INCLUSION BODY MYOSITIS (SIBM)**

Gnanasakthy A¹, DeMuro C¹, Lewis S¹, Tseng B²,¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Novartis Pharmaceuticals, Cambridge, MA, USA

PRM108 F13 pgA29 **HEALTH-RELATED QUALITY OF LIFE AMONG ESRF PATIENTS IN PAKISTAN: A CROSS-SECTIONAL APPROACH USING WHOQOL-BREF**

Iqbal MZ¹, Iqbal MS², Iqbal MW³, Bahari MB², Nasir S⁴,¹Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, ²Department of Clinical Pharmacy

& Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia,³Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia, ⁴Nishtar Hospital, Multan, Pakistan

- PRM109 F14** *pgA29* **CHALLENGES IN TRANSLATING THE CONNERS 3RD EDITION–PARENT INTO 12 LANGUAGES**
Verne A, Bailly C, Rouillat C, Mapi, Lyon, France
- PRM110 F15** *pgA29* **THE IMPORTANCE OF ANCHOR BASED MINIMAL CLINICALLY IMPORTANT DIFFERENCE (MCID) TO HEALTH TECHNOLOGY ASSESSMENT OF ESTABLISHED INTRANASAL ALLERGIC RHINITIS TREATMENTS**
Brixner D¹, Meltzer EO², Morland K³, Carroll CA³, Lipworth BJ⁴,¹University of Utah, Salt Lake City, UT, USA, ²Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA, ³Xcenda, Palm Harbor, FL, USA, ⁴Ninewells Hospital and School of Medicine, Dundee, UK
- PRM111 F16** *pgA29* **CAN'T WE JUST USE THIS PORTUGUESE TRANSLATION IN BRAZIL? ANALYSING WHY THERE IS MORE TO COUNTRY-SPECIFIC PROS THAN TICKING/CHECKING BOXES**
Simpson H, Bellhouse G, Neal R, Two R, PharmaQuest Ltd., Bloxham, UK
- PRM112 G1** *pgA29* **VALIDATION OF A VITALITY QUOTIENT TO MEASURE THE EFFECT OF FOOD SUPPLEMENTS ON FATIGUE IN HEALTHY SUBJECTS**
Allaert F¹, Courau S², Forestier A²,¹Medical evaluation Chair ESC Dijon, Dijon, France, ²Merck CH, Dijon, France
- PRM113 G2** *pgA29* **CHALLENGES FACED DURING LINGUISTIC VALIDATION FOR SOUTH AFRICA**
Townes L, Williams H, **Anderson H**, Gergovich B, ICON Plc, Oxford, UK
- PRM114 G3** *pgA30* **RECOMMENDATIONS FOR THE LINGUISTIC VALIDATION OF PEDIATRIC CLINICAL OUTCOMES ASSESSMENTS**
Gawlicki M¹, Brandt B¹, McKown S¹, **Talbert M**²,¹Corporate Translations Inc, East Hartford, CT, USA, ²Corporate Translations Inc, Chicago, IL, USA
- PRM115 G4** *pgA30* **USE OF WORK PRODUCTIVITY ENDPOINTS IN CLINICAL STUDIES: A REVIEW BY DISEASE STATE AND MEASUREMENT TYPE**
Popelar B, Walters T, Zagadailov EA, Houle C, Duhig A, Xcenda, Palm Harbor, FL, USA
- PRM116 G5** *pgA30* **REVIEW OF CAREGIVER BURDEN SCALES FOR PATIENTS WITH VISUAL IMPAIRMENT IN JAPAN**
Narimatsu A, Ishii K, Adachi K, Bayer Yakuhin Ltd., Tokyo, Japan
- PRM117 G6** *pgA30* **DEVELOPMENT OF ELECTRONIC DIARY IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS**
Gilchrist K, **Vallow S**, GlaxoSmithKline, King of Prussia, PA, USA
- PRM118 G7** *pgA30* **ASSESSMENT OF TREATMENT ADHERENCE AND QUALITY OF LIFE IN DIABETIC PATIENTS TREATED WITH INSULIN IN TWO COLOMBIAN CITIES**
Medina Morales DA, Machado Alba JE, Echeverry-Cataño LF, Londoño-Builes MJ, Universidad Tecnológica de Pereira, Pereira, Colombia
- PRM119 G8** *pgA30* **IMPORTANCE OF THE CONCEPTUAL DEFINITION OF PRO MEASURES: A CASE STUDY WITH THE LINGUISTIC VALIDATION OF THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE (IBS-QOL) INSTRUMENT IN 17 ASIATIC LANGUAGES**
Lambe J¹, Patrick DL², Torabully N¹, Skerritt B³, **Acquadro C**⁴,¹Mapi, Lyon, France, ²University of Washington, Seattle, WA, USA, ³ICON, Dublin, Ireland, ⁴Mapi Research Trust, Lyon, France

RESEARCH ON METHODS - Statistical Methods

- PRM120 G9** *pgA31* **EVALUATION OF MATCHING-ADJUSTED INDIRECT COMPARISON IMPLEMENTED BY A RESAMPLING METHOD**
Wang J¹, Odom D², Chirila C¹, Zheng Q¹,¹RTI-Health Solutions, Research Triangle Park, NC, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA
- PRM121 G10** *pgA31* **A SYSTEMATIC REVIEW OF THE METHODOLOGICAL QUALITY OF NETWORK META-ANALYSES**
Chambers J¹, Naci H², Wouters O², Pyo J¹, Gunjal S³, Kennedy I⁴, Hoey M⁴, Winn A⁵, Neumann PJ⁶,¹Tufts Medical Center, Boston, MA, USA, ²London School of Economics, London, UK, ³Precision Health Economics, Austin, TX, USA, ⁴Royal Victoria Hospital, Belfast, UK, ⁵The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁶Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
- PRM122 G11** *pgA31* **APPLICATION OF DIFFERENCE-IN-DIFFERENCE METHODOLOGY IN COMPARATIVE EFFECTIVENESS RESEARCH WITH UNBALANCED GROUPS**
Li Y¹, Zhou H², Ko JJ¹, Hawker K¹, Nazareth T¹, Arcona S¹, Sasane R¹,¹Novartis Pharmaceuticals, East Hanover, NJ, USA, ²KmK Consulting Inc. for Novartis Pharmaceuticals, Florham Park, NJ, USA
- PRM123 G12** *pgA31* **LOW-MOLECULAR-WEIGHT HEPARIN TREATMENT OF DEEP-VEIN THROMBOSIS: A NETWORK META-ANALYSIS**
Diaz JP¹, Soto Molina H², Marquez M³, Escobar Juárez Y²,¹Universidad Nacional Autónoma de México, México D.F., Mexico, ²HS Estudios Farmacoeconómicos, Mexico City, Mexico, ³Universidad Autónoma Metropolitana, México D.F., Mexico
- PRM124 G13** *pgA31* **ALTERNATIVE WEIGHTING APPROACHES FOR MATCHING ADJUSTED INDIRECT COMPARISONS (MAIC)**

Belger M¹, Brnabic A², Kadziola Z³, Petto H³, **Faries D**⁴,¹Eli Lilly and Company (Lilly UK), Surrey, UK, ²Eli Lilly, Sydney, Australia, ³Eli Lilly Regional Operations GmbH, Vienna, Austria, ⁴Eli Lilly, Indianapolis, IN, USA

PRM125 G14 pgA32 PSYCHOTROPIC PHARMACOTHERAPY ASSOCIATED WITH QT PROLONGATION AMONG VETERANS WITH POSTTRAUMATIC STRESS DISORDER

Stock EM¹, Zeber JE¹, McNeal CJ², Banchs JE², Copeland LA¹,¹Center for Applied Health Research - Central Texas Veterans Health Care System jointly with Baylor Scott & White Health, Temple, TX, USA,²Baylor Scott & White Health, Temple, TX, USA

PRM126 G15 pgA32 ENSURING APPLICABILITY OF REAL WORLD EVIDENCE TO INDIVIDUAL PATIENT DECISION MAKING

Numapau NO¹, Hess LM¹, Brnabic A¹, Cuyun Carter G¹, Araujo AB², Robinson R¹, Swindle R¹,¹Eli Lilly, Indianapolis, IN, USA, ²Eli Lilly, Indianapolis, IN, USA

PRM127 G16 pgA32 EMPIRICAL ESTIMATION OF STATISTICAL POWER AND MINIMUM NUMBER OF STUDIES NEEDED FOR A NETWORK META-ANALYSIS

Parks DC¹, Lee K¹, Dabbous O², Lin X¹, Cockle S³, Stanford R⁴, Alfonso-Cristancho R⁵,¹GSK, Phoenixville, PA, USA, ²GlaxoSmithKline, King of Prussia, PA, USA, ³GSK, London, UK, ⁴GSK, Research Triangle Park, NC, USA, ⁵GlaxoSmithKline (GSK), King of Prussia, PA, USA

PRM128 G17 pgA32 ECONOMICS OF DIABETES MELLITUS: THEORY AND EVIDENCE FOR BRAZILIAN DATA IN 2008

Balbinotto G¹, Wiest R², Jacinto P³,¹Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, PORTO ALEGRE, Brazil, ³pu/rs, PORTO ALEGRE, Brazil

PRM129 G18 pgA32 CLUSTER ANALYSIS OF HEALTHCARE COSTS PATTERNS IN END STAGE RENAL DISEASE PATIENTS WHO INITIATED HEMODIALYSIS

Liao M¹, **Li Y**², Kianifard F², Obi E³, Arcona S²,¹KMK Consulting Inc., Florham Park, NJ, USA, ²Novartis Pharmaceuticals, East Hanover, NJ, USA, ³Rutgers University, Piscataway, NJ, USA

PRM130 G19 pgA33 INCLUSION OF MULTIPLE STUDIES IN MATCHING ADJUSTED INDIRECT COMPARISONS (MAIC)

Belger M¹, Brnabic A², Kadziola Z³, Petto H³, **Faries D**⁴,¹Eli Lilly and Company (Lilly UK), Surrey, UK, ²Eli Lilly, Sydney, Australia, ³Eli Lilly Regional Operations GmbH, Vienna, Austria, ⁴Eli Lilly, Indianapolis, IN, USA

PRM131 G20 pgA33 CLASSIFICATION TREE ANALYSIS OF THE LIKELIHOOD OF CLOPIDOGREL TREATMENT IN A COHORT OF PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERY DISEASE

Reed Chase M¹, Friedman H², Navaratnam P², Heithoff K¹, Simpson Jr. RJ³,¹Merck & Co., Kenilworth, NJ, USA, ²DataMed Solutions LLC, New York City, NY, USA, ³University of North Carolina, Chapel Hill, NC, USA

RESEARCH ON METHODS - Study Design

PRM132 G21 pgA33 HOW MANY SUBJECTS ARE ENOUGH FOR SYMPTOM-FOCUSED CONCEPT ELICITATION STUDIES? A RETROSPECTIVE ANALYSIS OF SATURATION ACROSS TWENTY-SIX STUDIES

Lamoureux RE, Shields A, **Stokes J**, Yaworsky A, Galipeau N, Adelphi Values USA, Boston, MA, USA

PRM133 H1 pgA33 EXPLORING THE REAL WORLD SETTING OF CHRONIC IDIOPATHIC URTICARIA AND PHYSICIAN ATTITUDES TOWARDS IT IN THE US

Gabriel S¹, Herrera V², Hoskin B³, Anderson P³, Karagiannis T⁴,¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ²Novartis Pharmaceuticals, East Hanover, NJ, USA, ³Adelphi Real World, Macclesfield, MA, USA, ⁴Jefferson School of Population Health for Novartis Pharmaceuticals, East Hanover, NJ, USA

PRM134 H2 pgA33 HTA DECISIONS AND COMPARATOR CHANGES OVER TIME IN RHEUMATOID ARTHRITIS

Sliman RC, Rubinstein ER, Versoza L, Lurie BF, Westbrook L, Sanchez DP, Rubinstein JL, Ho Y, Context Matters, Inc., New York, NY, USA

PRM135 H3 pgA33 RESPONSE RATES IN DIRECT-TO-PATIENT SURVEYS

Goolsby Hunter A, Brenneman S, Optum, Eden Prairie, MN, USA

PRM136 H4 pgA34 PHARMACOECONOMICS EDUCATION IN WHO EASTERN MEDITERRANEAN REGION

Al-Efan QM¹, Al-Emam S¹, Mukattash TL¹, Mhaidat NM¹, Al-Abadi I², Rascati K³,¹Jordan University of Science & Technology, Irbid, Jordan, ²University of Jordan, Amman, Jordan, ³University of Texas at Austin, Austin, TX, USA

PRM137 H5 pgA34 AN INVESTIGATION INTO RHEUMATOID ARTHRITIS COMPARATORS AND SUBPOPULATIONS

Lurie BF, Rubinstein ER, Versoza L, Sliman RC, Westbrook L, Sanchez DP, Rubinstein JL, Ho Y, Context Matters, New York, NY, USA

PRM138 H6 pgA34 A PRAGMATIC LITERATURE REVIEW OF NETWORK META-ANALYSES OF DISEASE-MODIFYING DRUGS IN THE TREATMENT OF MULTIPLE SCLEROSIS

Phillips AL¹, Beckerman R², Smith NJ², Locklear JC¹, Jiang Y², Solon C³,¹EMD Serono, Inc., Rockland, MA, USA, ²CBPartners, New York, NY, USA, ³CBPartners, San Francisco, CA, USA

PRM139 H7 pgA34 KNOWLEDGE AND AWARENESS OF ORAL CANCER IN GUNTUR AREA, SOUTH INDIA

Vasireddy KS, Chalapathi Institute Of Pharmaceutical Sciences, Guntur, India

RESEARCH ON METHODS - Conceptual Papers

PRM140 H8 pgA34 EXPLORING HETEROGENEITY IN ATTRIBUTE PROCESSING STRATEGIES: USE OF HYBRID RANDOM

UTILITY MAXIMIZATION-RANDOM REGRET MINIMIZATION (RUM-RRM) MODELS IN A DISCRETE CHOICE EXPERIMENT (DCE)

Chaugule S¹, Hay JW¹, Young G²,¹University of Southern California, Los Angeles, CA, USA, ²Children's Hospital Los Angeles, Los Angeles, CA, USA

PRM141 H9 pgA34 AN ANALYTICAL CRITERION FOR JUDGING THE EXTENDED DOMINANCY OF A NEW TECHNOLOGY COMPARED TO THE STANDARD OF CARE AND PLACEBO CONTROL

Kamae I¹, Sugimoto T¹, Yamabe K²,¹The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, ²Takeda Pharmaceutical Company Ltd., Tokyo, Japan

PRM142 H10 pgA35 THE EXPANDED NUMBER NEEDED TO TREAT: APPLYING THE CONCEPT OF NNT TO CONTINUOUS HEALTH ECONOMIC OUTCOMES

O'Day K, **Campbell DJ**, Xcenda, Palm Harbor, FL, USA

PRM143 H11 pgA35 IMPORTANT STATISTICAL CONSIDERATIONS FOR DEVELOPING EQUATIONS FOR DISEASE SIMULATORS

Ishak KJ¹, Kansal A², Krotneva M¹, Tarko L³, Tafazzoli A²,¹Evidera, St-Laurent, QC, Canada, ²Evidera, Bethesda, MD, USA, ³Evidera, Lexington, MA, USA

PRM144 H12 pgA35 PACE CONTINUOUS INNOVATION INDICATORS—A NOVEL TOOL TO MEASURE PROGRESS IN CANCER TREATMENTS

Paddock S¹, Brum LM¹, Sorrow K¹, Thomas S¹, Spence S¹, Maulbecker-Armstrong C², Goodman C³, Peake M⁴, McVie G⁵, Ramers-Verhoeven C⁶, Geipel G⁷, Li R¹,¹Rose Li and Associates, Inc., Bethesda, MD, USA, ²German Ministry of Health, Wiesbaden, Germany, ³The Lewin Group, Falls Church, VA, USA, ⁴University of Leicester, Leicester, UK, ⁵European Institute of Oncology, Milan, Italy, ⁶Eli Lilly and Company, Houten, The Netherlands, ⁷Eli Lilly and Company, Indianapolis, IN, USA

PRM145 H13 pgA35 REVIEWING CLINICAL OUTCOME ASSESSMENT USAGE IN CLINICAL TRIALS: INTRODUCING THE COLA METHODOLOGY

Trigg A, Kitchen H, Willgoss TG, Meysner S, **Humphrey L**, Abacus International, Manchester, UK

PRM146 H14 pgA35 ADVANCING METHODS OF HTA: OPTIMISING MONITORING TESTS TO MEET VALUE TARGETS

McCabe C, Paulden M, **Akude P**, University of Alberta, Edmonton, AB, Canada

PRM147 H15 pgA36 THE PROCESSES FOR A COMMON QUALITY ASSURANCE APPROACH TO MULTI-CENTRE CLINICAL TRIALS – THE MARS EXCITE EXPERIENCE

Aziziyeh A¹, Easty T², Khayat Z¹, Kozlowski N³, Bowen J⁴, Rac V⁵, Garrity C⁶, Levin L¹,¹MaRS Discovery District, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Applied Health Research Centre, Toronto, ON, Canada, ⁴St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Ottawa Hospital Research Institute, Ottawa, ON, Canada

PRM148 H16 pgA36 INNOVATION IN THE DEVELOPMENT AND VALIDATION OF CLINICAL OUTCOME ASSESSMENTS (COA): AN EXPLORATION OF PATIENT-CENTERED CREATIVE METHODOLOGIES

Meysner S, Willgoss TG, Kitchen H, Trigg A, **Humphrey L**, Abacus International, Manchester, UK

PRM149 H17 pgA36 COMPARING THE ADOPTION OF EPRO IN CLINICAL RESEARCH TO EMR IN CLINICAL PRACTICE – WHY CLINICAL PRACTICE IS AHEAD OF RESEARCH WITH TECHNOLOGY USE

Ross J, Holzbaur E, Rothrock T, Wade M, Almac Clinical Technologies, Souderton, PA, USA

PRM150 H18 pgA36 METHODS AND CONTEXT FOR THE PRODUCTION OF RAPID REVIEWS

Kato EU¹, Hartling L², Guise J³,¹AHRQ, Rockville, MD, USA, ²University of Alberta, Edmonton, AB, Canada, ³Oregon Health & Science University, Portland, OR, USA

PRM151 H19 pgA36 RESOURCE MODELLING: THE MISSING PIECE OF THE HTA JIGSAW?

Thokala P¹, Dixon S¹, Jahn B²,¹University of Sheffield, Sheffield, UK, ²University for Health Sciences, Medical Informatics and Technology (UMIT), Tirol, Austria

PRM152 H20 pgA36 DATA CLEANING PAPER PATIENT REPORTED OUTCOME (PRO) DATA VERSUS ELECTRONIC PATIENT REPORTED OUTCOME (EPRO) DATA

Ross J, Holzbaur E, Wade M, Rothrock T, Almac Clinical Technologies, Souderton, PA, USA

PRM153 H21 pgA37 RETHINKING COST-EFFECTIVENESS IN THE ERA OF ZERO HEALTHCARE SPENDING GROWTH

Arbel R¹, Greenberg D²,¹Sapir College, Sderot, Israel, ²Ben-Gurion University of the Negev, Beer-Sheva, Israel

PRM154 I1 pgA37 THE ELECTRONIC AGE: INTEGRATING EPRO/EOA TO REDUCE PATIENT, SITE, AND STUDY TEAM BURDEN

Holzbaur E, Ross J, Wade M, Rothrock T, Almac Clinical Technologies, Souderton, PA, USA

PRM155 I2 pgA37 ADOPTING SOFTWARE ENGINEERING BEST PRACTICES IN THE FIELD OF PHARMACOECONOMICS CAN INCREASE THE TRANSPARENCY OF AND CONFIDENCE IN OUR HEALTH ECONOMIC MODELS

Dasbach EJ¹, Kruger M², **Prabhu V**¹,¹Merck & Co. Inc., North Wales, PA, USA, ²Merck & Co., Inc., Boston, MA, USA

PRM156 I3 pgA37 DIRECTLY ELICITING PERSONAL UTILITY FUNCTIONS: A NEW WAY TO VALUE HEALTH-RELATED QUALITY OF LIFE

Shah K¹, Devlin N¹, Mulhern B², van Hout B²,¹Office of Health Economics, London, UK, ²University of Sheffield,

MEDICAL DEVICE/DIAGNOSTICS - Clinical Outcomes Studies

- PMD1 14** *pgA37* **MAJOR AND MINOR ADVERSE EVENTS IN PATIENTS WERE SUBJECTED IN CARDIAC RHYTHM MANAGEMENT DEVICES (CRMD'S) THERAPY AND THEIR FINANCIAL IMPLICATION: A PROSPECTIVE SINGLE-CENTER TWO YEARS SURVEY**
Fanourgiakis JA¹, Simantirakis E², Kanoupakis E², Chrysostomakis S², Chlouverakis G³, Vardas P^{2,1}, Department of Cardiology, Heraklion University Hospital, Crete, Greece. Department of Accounting and Finance, School of Economics and Management, T.E.I. Heraklion, Crete, Greece. Department of Business Administration, T.E.I. Agios Nikolaos, Crete, Greece, Heraklion, Greece, ²Department of Cardiology, Heraklion University Hospital, Heraklion, Greece, ³University of Crete, Heraklion, Greece
- PMD2 15** *pgA38* **RELATIONSHIP BETWEEN ECHOCARDIOGRAPHIC MARKERS AND INDUCIBILITY OF VENTRICULAR ARRHYTHMIAS IN ISCHAEMIC CARDIOMYOPATHY PATIENTS**
 Kanoupakis E¹, **Fanourgiakis JA**², Mavrakis H¹, Kallergis E¹, Kouvidis E¹, Roufas K¹, Vardas P^{1,1}, Department of Cardiology, Heraklion University Hospital, Heraklion, Greece, ²Department of Cardiology, Heraklion University Hospital, Crete, Greece. Department of Accounting and Finance, School of Economics and Management, T.E.I. Heraklion, Crete, Greece. Department of Business Administration, T.E.I. Agios Nikolaos, Crete, Greece, Heraklion, Greece
- PMD3 16** *pgA38* **COMPARISON OF QUANTIFERON TB-GOLD (QFT-GIT) TEST VERSUS TUBERCULIN SKIN TEST (TST) FOR LATENT TUBERCULOSIS INFECTION (LTBI) SCREENING AMONG NATIONAL GUARD GENERAL POPULATION IN SAUDI ARABIA**
El Beltagy K, King Abdeaziz medical city, Riyadh, Saudi Arabia
- PMD4 17** *pgA38* **UTERINE FIBROID TREATMENT PATTERNS IN THE THREE YEARS FOLLOWING DIAGNOSIS**
Bonafede MM¹, Riehle E², Pohlman S³, Troeger K³, ¹Truven Health Analytics, Cambridge, MA, USA, ²Truven Health Analytics, Bethesda, MD, USA, ³Hologic, Inc., Marlborough, MA, USA
- PMD5 18** *pgA38* **COMPARATIVE EFFECTIVENESS OF FIBRIN SEALANTS IN CARDIAC SURGERY**
 Arnold MR¹, Ito D¹, Magee G², Xiong Y¹, Testa D³, **Rubinstein M**¹, Tackett S^{1,1}, Baxter Healthcare Corporation, Westlake Village, CA, USA, ²Premier Incorporated, Charlotte, NC, USA, ³Seven of Nine Systems, Studio City, CA, USA
- PMD6 19** *pgA38* **ALLOGENEIC PERIPHERAL BLOOD VERSUS BONE MARROW HEMATOPOIETIC CELL TRANSPLANTATION FROM UNRELATED DONORS: A META-ANALYSIS**
Arora P¹, Vanness DJ¹, Saber W^{2,1}, University of Wisconsin-Madison, Madison, WI, USA, ²Medical College of Wisconsin, Milwaukee, WI, USA
- PMD7 110** *pgA38* **TIME-DEPENDENCE OF FIRST APPROPRIATE THERAPY IN PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER DEFIBRILLATOR PATIENTS: IS DEVICE REPLACEMENT NECESSARY IN PATIENTS WITHOUT PRIOR ICD INTERVENTIONS?**
 Kanoupakis E¹, **Fanourgiakis JA**², Kallergis E¹, Mavrakis H¹, Maragoudakis S¹, Vernardos M¹, Chlouverakis G³, Vardas P^{1,1}, Department of Cardiology, Heraklion University Hospital, Heraklion, Greece, ²Department of Cardiology, Heraklion University Hospital, Crete, Greece. Department of Accounting and Finance, School of Economics and Management, T.E.I. Heraklion, Crete, Greece. Department of Business Administration, T.E.I. Agios Nikolaos, Crete, Greece, Heraklion, Greece, ³University of Crete, Heraklion, Greece
- PMD8 111** *pgA39* **CAN SEROLOGIC MARKERS OF FIBROSIS PREDICT FUTURE SHOCKS IN ICD RECIPIENTS WITH DILATED CARDIOMYOPATHY?**
 Kanoupakis E¹, **Fanourgiakis JA**², Kallergis E¹, Mavrakis H¹, Saloustris I¹, Koutalas E¹, Vernardos M¹, Chlouverakis G³, Vardas P^{1,1}, Department of Cardiology, Heraklion University Hospital, Heraklion, Greece, ²Department of Cardiology, Heraklion University Hospital, Crete, Greece. Department of Accounting and Finance, School of Economics and Management, T.E.I. Heraklion, Crete, Greece. Department of Business Administration, T.E.I. Agios Nikolaos, Crete, Greece, Heraklion, Greece, ³University of Crete, Heraklion, Greece
- PMD9 112** *pgA39* **LONG TERM FOLLOW UP OF PRIMARY AND SECONDARY PREVENTION IMPLANTABLE CARDIOVERTER DEFIBRILLATOR PATIENTS: "REAL-WORLD" DATA FROM THE ISLAND OF CRETE**
 Kanoupakis E¹, **Fanourgiakis JA**², Mavrakis H¹, Kallergis E¹, Petousis S¹, Vernardos M¹, Chlouverakis G³, Vardas P^{1,1}, Department of Cardiology, Heraklion University Hospital, Heraklion, Greece, ²Department of Cardiology, Heraklion University Hospital, Crete, Greece. Department of Accounting and Finance, School of Economics and Management, T.E.I. Heraklion, Crete, Greece. Department of Business Administration, T.E.I. Agios Nikolaos, Crete, Greece, Heraklion, Greece, ³University of Crete, Heraklion, Greece
- PMD10 113** *pgA39* **PHARMACOEPIDEMOLOGY OF CELLULAR/TISSUE DERIVED PRODUCTS FOR THE TREATMENT OF DIABETIC FOOT ULCERS IN OUTPATIENT CARE SETTINGS**
Gilligan AM, Waycaster CR, Smith & Nephew Inc., Fort Worth, TX, USA
- PMD11 114** *pgA39* **EPIDEMIOLOGY OF ADVANCED THERAPIES FOR THE TREATMENT OF DIABETIC FOOT ULCERS IN OUTPATIENT CARE SETTINGS**
Gilligan AM, Waycaster CR, Smith & Nephew Inc., Fort Worth, TX, USA

PMD12 J1 *pgA39* **EXAMINATION OF INTERVAL INCIDENCE OF COLORECTAL CANCER (CRC) AT SUBSEQUENT COLONOSCOPY OVER TIME: POPULATION-BASED RETROSPECTIVE COHORT STUDY**
Ren J¹, Asche CV¹, Kirkness CS¹, Puli S²,¹University of Illinois College of Medicine at Peoria, Peoria, IL, USA, ²OSF Medical Group, Peoria, IL, USA

MEDICAL DEVICE/DIAGNOSTICS - Cost Studies

- PMD13 J2** *pgA40* **BUDGET IMPACT MODEL OF A BLOOD BASED PROTEOMIC CLASSIFIER FOR INDETERMINATE PULMONARY NODULES**
Aggarwal J¹, Goss T², Mathews C¹, Kearney P³, Diette G⁴,¹Boston Healthcare, Boston, MA, USA, ²Boston Healthcare Associates, Boston, MA, USA, ³IndiDx, Seattle, WA, USA, ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- PMD14 J3** *pgA40* **AN ECONOMIC MODEL OF THE IMPACT OF DIGITAL MEDICINES WITH A MOBILE APPLICATION IN PATIENTS WITH COMORBID HYPERTENSION, DIABETES, AND HYPERCHOLESTEROLEMIA**
Kim YA¹, Raja P¹, DiCarlo L¹, Viridi N¹, Park H²,¹Proteus Digital Health, Redwood City, CA, USA, ²University of Florida, Gainesville, FL, USA
- PMD15 J4** *pgA40* **MEDICARE BENEFICIARY OUT-OF-POCKET SPENDING FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION: A BUDGET ANALYSIS**
Armstrong S¹, Amorosi SL², Erickson G¹, Patel P², Stein K²,¹GfK Custom Research, Wayland, MA, USA, ²Boston Scientific, Marlborough, MA, USA
- PMD16 J5** *pgA40* **ECONOMIC ANALYSIS OF EVARRESTTM COMPARED WITH STANDARD CARE IN CHALLENGING LIVER SURGICAL BLEEDING POPULATIONS: A U.S. HOSPITAL PERSPECTIVE**
Corral M¹, Jamous N², Ferko N³, Hogan A³, Batiller J¹, Kocharian R¹,¹Ethicon Biosurgery, Somerville, NJ, USA, ²Ethicon Biosurgery, Berkshire, UK, ³Cornerstone Research Group Inc., Burlington, ON, Canada
- PMD17 J6** *pgA40* **CLINICAL AND BUDGET IMPACT OF USING A TEST TO DETECT KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN THE UNITED STATES**
Cheng J¹, Hertz D², Huang J¹, Poullos N¹,¹Roche Molecular Systems, Inc., Pleasanton, CA, USA, ²GfK Custom Research, Wayland, MA, USA
- PMD18 J7** *pgA40* **THE USE OF ULTRASONIC ENERGY IN MASTECTOMY AND LUMPECTOMY PROCEDURES: A BUDGET IMPACT ANALYSIS**
Ondrejicka DA, Goldstein LJ, Johnson and Johnson Medical Companies, Markham, ON, Canada
- PMD19 J8** *pgA41* **BUDGET IMPACT OF PERCUTANEOUS ENDOVASCULAR ABDOMINAL AORTA ANEURYSM (AAA) REPAIR COMPARED TO STANDARD ENDOVASCULAR REPAIR IN CANADIAN HOSPITALS**
Ondrejicka DA, Hazel M, Johnson and Johnson Medical Companies, Markham, ON, Canada
- PMD20 J9** *pgA41* **SAFETY PEN NEEDLE (SPN) DEVICES IN THE ACUTE CARE SETTING: AN ANALYSIS OF HEALTH RESOURCE UTILIZATION (HRU) IN THE UNITED STATES**
DiMario S¹, Smallwood C², Chandran A¹, Saltiel-Berzin R¹,¹Becton Dickinson, Franklin Lakes, NJ, USA, ²Becton Dickinson, Mississauga, ON, Canada
- PMD21 J10** *pgA41* **AN ASSESSMENT OF THE ECONOMIC IMPACT OF THE ADOPTION OF A NEW MECHANICAL FIXATION DEVICE ALONG WITH A NEW SKIRTED INTRA-PERITONEAL ONLY MESH (IPOM) ON HOSPITAL COSTS OF OPEN VENTRAL HERNIA REPAIR SURGERIES**
Panish JM¹, Chekan E², Roy S¹,¹Ethicon, Somerville, NJ, USA, ²Johnson & Johnson (Ethicon), Cincinnati, OH, USA
- PMD22 J11** *pgA41* **COST ANALYSES OF LUTONIX® 035 DCB PTA CATHETERS FOR THE TREATMENT OF FEMOROPLOPLITEAL ARTERY STENOSIS: A U.S. HOSPITAL PERSPECTIVE**
Delatore P¹, Hollmann S², Ferko N²,¹CR Bard Inc., Murray Hill, NJ, USA, ²Cornerstone Research Group Inc., Burlington, ON, Canada
- PMD23 J12** *pgA41* **IMPACT OF SAMPLE COLLECTION METHOD FOR EGFR MUTATION TESTING: RESULTS OF BLOOD-BASED AND TISSUE-BASED COBAS® EGFR MUTATION TESTING IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NSCLC IN THE US**
Poullos N¹, Hristova-Neeley D², Gavaghan M²,¹Roche Molecular Systems, Inc., Pleasanton, CA, USA, ²GfK, Wayland, MA, USA
- PMD24 J13** *pgA42* **A MODEL TO EXPLORE THE POTENTIAL BUDGET IMPACT OF A NOVEL SCREENING TOOL FOR THE DETECTION OF SUBCLINICAL REJECTION AMONG KIDNEY TRANSPLANT PATIENTS**
Inocencio TJ¹, Jaglinski K², Uchida H², Hughes KE¹,¹Avalere Health LLC, Washington, DC, USA, ²Immucor, Inc., Waukesha, WI, USA
- PMD25 J14** *pgA42* **BUDGET IMPACT AND COST- EFFECTIVENESS OF AN INNOVATIVE BLOOD GLUCOSE MEASUREMENT DEVICE USING PATTERN ALERT TECHNOLOGY IN INSULIN-TREATED DIABETICS IN THE UNITED STATES**
Krumreich J¹, Froehlich N¹, Schauf M², Drapkin J², Zoellner YF³,¹Econ-Epi, Wentorf/Hamburg, Germany, ²Lifescan, a Johnson & Johnson company, Wayne, PA, USA, ³Hamburg University of Applied Sciences, Hamburg, Germany
- PMD26 K1** *pgA42* **CLINICAL AND COST OUTCOMES FROM DIFFERENT HYALURONIC ACID TREATMENTS IN PATIENTS**

WITH KNEE OSTEOARTHRITIS

Dasa V¹, DeKoven M², Lim S³, Long K⁴, Heeckt P⁴,¹Louisiana State University, New Orleans, LA, USA, ²IMS Health, Fairfax, VA, USA, ³Seikagaku Corporation, Tokyo, Japan, ⁴Bioventus LLC, Durham, NC, USA

- PMD27 K2** *pgA42* **ECONOMIC VALUE OF PREVENTING CENTRAL VENOUS CATHETER SEPSIS INFECTIONS WITH EARLY CANNULATION ARTERIOVENOUS GRAFTS (ECAVGS) COMPARED TO NON-ECAVGS**
Mohr BA, Trovillion PJ, W. L. Gore & Associates, Inc., Flagstaff, AZ, USA
- PMD28 K3** *pgA42* **ECONOMIC IMPACT OF OPEN MECHANICAL STAPLING VS. MANUAL SUTURING IN ILEOCOLIC ANASTOMOSIS IN MEXICAN PUBLIC HEALTHCARE INSTITUTIONS**
Zanela OO¹, Cabra HA², Sanchez D¹,¹Johnson & Johnson Medical Mexico, MEXICO CITY, Mexico, ²Johnson & Johnson Medical, Mexico, D.F., Mexico
- PMD29 K4** *pgA43* **ECONOMIC IMPACT DERIVED FROM THE USE OF A CATHETER IMPREGNATED WITH ANTIBIOTIC IN PEDIATRIC PATIENTS WITH HYDROCEPHALUS TREATED WITH EXTERNAL SHUNTS IN MEXICO**
Zanela OO¹, Sanchez D¹, Cabra HA²,¹Johnson & Johnson Medical Mexico, MEXICO CITY, Mexico, ²Johnson & Johnson Medical, Mexico, D.F., Mexico
- PMD30 K5** *pgA43* **COST-UTILITY OF DEEP BRAIN STIMULATION FOR THE TREATMENT OF ADVANCED PARKINSON'S DISEASE IN THE UNITED STATES**
Pietzsch JB¹, Garner AM¹, Marks WJ²,¹Wing Tech Inc., Menlo Park, CA, USA, ²University of California San Francisco, San Francisco, CA, USA
- PMD31 K6** *pgA43* **ECONOMIC OUTCOMES AMONG MEDICARE PATIENTS RECEIVING BIOENGINEERED CELLULAR TECHNOLOGIES FOR TREATMENT OF DIABETIC FOOT ULCERS**
Rice JB¹, Desai U¹, Ristovska L¹, Cummings AG¹, Birnbaum HG², Skornicki M³, Margolis D⁴, Parsons N³,¹Analysis Group, Inc., Boston, MA, USA, ²Analysis Group, Boston, MA, USA, ³Organogenesis, Canton, MA, USA, ⁴University of Pennsylvania, Philadelphia, PA, USA
- PMD32 K7** *pgA43* **COST-EFFECTIVENESS OF STIMULATION OF THE SPHENOPALATINE GANGLION (SPG) FOR THE TREATMENT OF CHRONIC CLUSTER HEADACHE: A MODEL-BASED ANALYSIS BASED ON THE PATHWAY CH-1 STUDY**
Pietzsch JB¹, Garner AM¹, Gaul C², May A³,¹Wing Tech Inc., Menlo Park, CA, USA, ²Migräne und Kopfschmerzambulanz Königstein, Königstein im Taunus, Germany, ³Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- PMD33 K8** *pgA43* **HUMANISTIC AND ECONOMIC OUTCOMES AMONG PATIENTS RECEIVING PERCUTANEOUS INTERVENTION**
Muragundi PM¹, Tumkur AM¹, Shetty R¹, Udupa N¹, Nagappa AN²,¹Manipal University, Manipal, India, ²Dept. of Pharmacy Management, MCOPS, Manipal University, Manipal, India
- PMD34 K9** *pgA43* **A SYSTEM DYNAMICS MODEL FOR THE COST-EFFECTIVENESS EVALUATION OF BACTERIAL WHOLE-GENOME SEQUENCING FOR DETECTING AND MONITORING OUTBREAKS OF MRSA**
Agirrezabal I¹, Buchanan-Hughes AM¹, Eddowes LA¹, Luheshi LM², Sagoo GS², Török ME³,¹Costello Medical Consulting Ltd., Cambridge, UK, ²PHG Foundation, Cambridge, UK, ³University of Cambridge, Cambridge, UK
- PMD35 K10** *pgA44* **COST-EFFECTIVENESS OF AQP4 ANTIBODY DETECTION WITH CELL-BASED ASSAY COMPARED WITH ELISA FOR DEVIC DISEASE DIAGNOSIS IN COLOMBIA**
Rosselli D¹, Acosta A¹, Castañeda C¹, Ruiz-Patiño A², Ruiz R¹,¹Pontificia Universidad Javeriana, Bogota, Colombia, ²Hospital Universitario San Ignacio, Bogotá, Colombia
- PMD36 K11** *pgA44* **COST EFFECTIVENESS OF LEFT ATRIAL APPENDAGE CLOSURE VERSUS WARFARIN FOR STROKE RISK REDUCTION IN NON-VALVULAR ATRIAL FIBRILLATION IN CMS PATIENTS**
Reddy V¹, Akehurst R², Amorosi SL³, Armstrong S⁴, Beard S⁵, Knight C⁵, Taggart C⁴, Holmes D⁶,¹Mount Sinai, New York, NY, USA, ²University of Sheffield, Sheffield, UK, ³Boston Scientific, Marlborough, MA, USA, ⁴GfK Custom Research, Wayland, MA, USA, ⁵BresMed, Sheffield, UK, ⁶Mayo Clinic, Rochester, MN, USA
- PMD37 K12** *pgA44* **A SYSTEM DYNAMICS MODEL FOR THE COST-EFFECTIVENESS EVALUATION OF BACTERIAL WHOLE-GENOME SEQUENCING FOR MONITORING OUTBREAKS OF CLOSTRIDIUM DIFFICILE**
Buchanan-Hughes AM¹, Agirrezabal I¹, Eddowes LA¹, Luheshi LM², Török ME³, Sagoo GS²,¹Costello Medical Consulting Ltd., Cambridge, UK, ²PHG Foundation, Cambridge, UK, ³University of Cambridge, Cambridge, UK
- PMD38 K13** *pgA44* **COSTS AND CONSEQUENCES OF DIALYSIS RELATED INFECTIONS: IMPLICATIONS FOR THE BUNDLED PAYMENTS FOR CARE IMPROVEMENT INITIATIVE**
Queeley GL, Campbell ES, Florida A&M University, Tallahassee, FL, USA
- PMD39 K14** *pgA44* **A COST-EFFECTIVENESS ANALYSIS OF BIOMARKER TESTING TO TARGET TREATMENT TO PATIENTS WITH MILD COGNITIVE IMPAIRMENT AT INCREASED RISK OF ALZHEIMER'S DISEASE**
Michaud TL, Kuntz K, University of Minnesota, Minneapolis, MN, USA
- PMD40 K15** *pgA44* **COST-EFFECTIVENESS ANALYSIS OF EXTERNAL LOOPING RECORDING COMPARED TO HOLTER MONITORING FOR SYNCOPE IN COLOMBIA**
Orozco JJ¹, Shrivastav M², Vilendrer S²,¹Medtronic, Medellin, Colombia, ²Medtronic, Minneapolis, MN, USA
- PMD41 K16** *pgA45* **THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE METAL STENTS IN TAIWAN**

Fang N¹, Yao M², Tseng T¹,¹Tunghai University, Taichung city, Taiwan, ²National Chiao Tung University, Hsinchu county, Taiwan

PMD42 K17 pgA45 ECONOMIC EVALUATION OF PACLITAXEL-ELUTING BALLOON CATHETER FOR PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) IN MEXICAN POPULATION WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE

Ceballos R¹, Orozco JJ², Soto H³, Carmona M⁴, Escobar Juárez Y⁴,¹Medtronic, Mexico, Mexico, ²Medtronic, Medellín, Colombia, ³Universidad Autonoma Metropolitana, México D.F., Mexico, ⁴HS Estudios Farmacoeconómicos, Mexico City, Mexico

PMD43 K18 pgA45 COST-ANALYSIS OF MEDIHONEY CALCIUM ALGINATE VERSUS AQUACEL AG DRESSING FOR CHRONIC LEG ULCERS TREATMENT UNDER THE BRAZILIAN PUBLIC PAYER PERSPECTIVE

Tolentino AC¹, Turkos M², Dick S²,¹Instituto de Cardiologia Aloysio de Castro, Rio de Janeiro, Brazil, ²Derma Sciences, Princeton, NJ, USA

PMD44 L1 pgA45 COST EFFECTIVENESS OF SACRAL NEUROSTIMULATION FOR OVERACTIVE BLADDER IN MEXICO

Soto H¹, Sanchez K², Escobar Juárez Y², Constanzo A², Ceballos R³,¹Universidad Autonoma Metropolitana, México D.F., Mexico, ²HS Estudios Farmacoeconómicos, Mexico City, Mexico, ³Medtronic, Mexico, Mexico

PMD45 L2 pgA45 CARDIOVERTER-DEFIBRILLATOR: THE CHOICE BETWEEN THE NEED AND LIMITED RESOURCES

Gurtskaya G, Kulkhan T, Sasykova A, Issatayeva N,Republican Center for Health Development, Astana, Kazakhstan

PMD46 L3 pgA45 COST-UTILITY OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION VERSUS ANTIDEPRESSANT THERAPY FOR TREATMENT-RESISTANT DEPRESSION

Gordon LG, Nguyen K,Griffith University, Logan, Australia

PMD47 L4 pgA46 FRACTIONAL FLOW RESERVE VERSUS CORONARY ANGIOGRAPHY GUIDED MANAGEMENT IN NON-ST ELEVATION MYOCARDIAL INFARCTION: A HEALTH ECONOMIC ANALYSIS

Nam J¹, Briggs A¹, Layland J¹, Oldroyd K², Curzen N¹, Sood A¹, Balachandran K¹, Das R¹, Eteiba H¹, Petrie M¹, Lindsay M¹, Watkins S¹, O'Donnell A¹, McConnachie A¹, Henderson R¹, Berry C¹,¹University of Glasgow, Glasgow, UK, ²West of Scotland Heart and Lung Centre, Glasgow, UK

PMD49 L6 pgA46 COST EFFECTIVENESS OF PRESCRIBING EVZIO FOR LAY HEROIN OVERDOSE REVERSAL

Holdford DA,Virginia Commonwealth University, Richmond, VA, USA

PMD51 L7 pgA46 ESTIMATING THE COST-EFFECTIVENESS OF LEFT ATRIAL APPENDAGE CLOSURE COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

Shih V, Devine B,University of Washington, Seattle, WA, USA

PMD52 L8 pgA46 SCREENING HIGH-RISK POPULATIONS FOR LATENT TUBERCULOSIS: A SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES

Campbell JR, Marra F,University of British Columbia, Vancouver, BC, Canada

PMD53 L9 pgA47 COST ATTRIBUTED TO PRODUCTIVITY LOSS IN PATIENTS SUBJECTED TO PACEMAKER (PM) AND IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (ICD) IMPLANTATION

Fanourgiakis JA¹, Simantirakis E², Kanoupakis E², Chrysostomakis S², Maniadakis N³, Kourlamba G³, Vardas P²,¹Department of Cardiology, Heraklion University Hospital, Crete, Greece. Department of Accounting and Finance, School of Economics and Management, T.E.I. Heraklion, Crete, Greece. Department of Business Administration, T.E.I. Agios Nikolaos, Crete, Greece, Heraklion, Greece, ²Department of Cardiology, Heraklion University Hospital, Heraklion, Greece, ³Department of Health Services Management, National School of Public Health, Athens, Greece, Athens, Greece

PMD54 L10 pgA47 DIFFUSION OF ULTRASOUND AMONG PHYSICIANS TREATING PATIENTS WITH RHEUMATOID ARTHRITIS: 2002-2013

Atzinger C, Schauer D, Wiggle P, Cavanaugh T, Kelton C, Guo JJ,University of Cincinnati, Cincinnati, OH, USA

PMD55 L11 pgA47 EVIDENCE OF A GAP IN CARE: UTILIZATION OF RADIOLOGIC DIAGNOSTIC IMAGING IN PATIENTS WITH AND WITHOUT IMPLANTABLE DEFIBRILLATORS

Nazarian S¹, Reynolds MR², **Ryan MP**³, Wolff SD⁴, Mollenkopf S⁵, Turakhia MP⁶,¹Johns Hopkins University School of Medicine, Baltimore, MD, USA, ²Harvard Clinical Research Institute, Boston, MA, USA, ³CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, ⁴Carnegie Hill Radiology, New York, NY, USA, ⁵Medtronic, Inc., Mounds View, MN, USA, ⁶Stanford University, Stanford, CA, USA

MEDICAL DEVICE/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies

PMD56 L12 pgA47 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS TREATED WITH CONTINUOUS AMBULATORY PERITONEAL DIALYSIS AND AUTOMATED PERITONEAL DIALYSIS IN SINGAPORE

Yang F¹, Griva K², Lau T³, Foo MW⁴, Mooppil N⁵, Newman SP⁶, Vathsala A³, Lee E³, Chia KS¹, Luo N¹,¹Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ²Department of Psychology, Faculty of Arts and Social Sciences, National University of Singapore, Singapore, Singapore, ³Division of Nephrology, University Medicine Cluster, National University Health System, Singapore, Singapore, ⁴Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore, Singapore, ⁵National Kidney Foundation, Singapore, Singapore, Singapore, ⁶Health Services Research, City University London, UK, UK

- PMD57 L13** *pgA47* **PATIENT'S PREFERENCES FOR DRY POWDER INHALER ATTRIBUTES IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A DISCRETE CHOICE EXPERIMENT**
Hawken NA¹, Aballéa S², Torvinen S³, Plich A⁴, Toumi M⁵,¹Creativ-Ceutical, Luxembourg, Luxembourg, ²Creativ-Ceutical, Paris, France, ³Teva Pharmaceuticals Europe B.V, Amsterdam, The Netherlands, ⁴Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, ⁵Université Claude Bernard Lyon I, Lyon, France
- PMD58 L14** *pgA48* **COMPARISON OF THE IASP GRADING SYSTEM AND S-LANSS IN IDENTIFICATION OF NEUROPATHIC PAIN IN PATIENTS WITH CHRONIC LOW BACK PAIN**
Gudala K¹, Bansal D¹, Ghai B²,¹National Institute of Pharmaceutical Education and Research, Mohali, India, ²Post Graduate Institute of Medical Education and Research, Mohali, India
- PMD59 L15** *pgA48* **MEASURING FUNCTION IN COGNITIVE IMPAIRMENT: A SUGGESTED TAXONOMY FOR CHARACTERIZING ASSESSMENT INSTRUMENTS**
Ung BL¹, Perfetto EM², Tom S¹, Pickering MK³, Yang K¹, Higa S¹,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland, School of Pharmacy, College Park, MD, USA, ³University of Maryland, School of Pharmacy, Baltimore, MD, USA
- PMD60 L16** *pgA48* **PATIENT FACTORS IN THE DECISION TO DELAY TOTAL KNEE ARTHROPLASTY**
Zhao R¹, Carlson AM², Ilfeld BM³, Berend KR⁴, **Stultz MR**⁵,¹University of Minnesota, Minneapolis, MN, USA, ²Data Intelligence Consultants, LLC, Eden Prairie, MN, USA, ³University of California San Diego, San Diego, CA, USA, ⁴Joint Implant Surgeons, Inc., New Albany, OH, USA, ⁵SPR Therapeutics, Cleveland, OH, USA

MEDICAL DEVICE/DIAGNOSTICS - Health Care Use & Policy Studies

- PMD61 L17** *pgA48* **INCREASED RATES OF SELF MONITORING OF BLOOD GLUCOSE TRANSLATES TO BETTER MARGINAL EFFECTS ON HBA1C CONTROL**
Agiro A¹, Xie Y¹, DeVries A¹, Bowman K², Carlisle SG³,¹HealthCore, Wilmington, DE, USA, ²Anthem, Baltimore, MD, USA, ³Anthem, Woodland Hills, CA, USA
- PMD62 L18** *pgA48* **USER EXPERIENCE A NOVEL, BUT CRITICAL ELEMENT IN PAYER AND PURCHASER VALUE ANALYSIS OF MEDICAL TECHNOLOGIES**
Garfield S, Zack L, GfK Custom Research, Wayland, MA, USA
- PMD63 M1** *pgA48* **A FRAMEWORK FOR COVERAGE DECISIONS FOR DIGITAL HEALTH TECHNOLOGIES**
Waterman J, Taggart C, Garfield S, GfK Custom Research, Wayland, MA, USA
- PMD64 M2** *pgA49* **COMPANION DEVICES: TRANSFORMATIVE MOBILE HEALTH TECHNOLOGY TOWARDS IMPROVED PATIENT CARE DELIVERY**
Chawla AS¹, Paul A¹, Horowicz-Mehler N², Faulkner EC³, Doyle JJ⁴,¹Quintiles Consulting, Durham, NC, USA, ²Quintiles Global Consulting, New York, NY, USA, ³Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA, ⁴Quintiles, Hawthorne, NY, USA
- PMD65 M3** *pgA49* **UNIVERSAL SCREENING IDENTIFIES HIGHER THYROID DYSFUNCTION IN PREGNANCY. EVIDENCE BASED META-ANALYSIS**
Sharma S¹, Bansal D², Gudala K³,¹National Institute of Pharmaceutical Education and Research, Mohali, India, ²National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India, ³National Institute of Pharmaceutical Education and Research, Mohali, India
- PMD66 M4** *pgA49* **CHARACTERIZATION OF EARLY STAGE BREAST CANCER PATIENT MANAGEMENT IN A PRACTICE SETTING WITH THE 21-GENE BREAST CANCER ASSAY**
Pecora A¹, Waintraub S¹, **Choi K**², Chao C³, Rothney M⁴,¹Regional Cancer Care Associates, Hakensack, NJ, USA, ²COTA, Inc., New York, NY, USA, ³Genomic Health, Inc., Redwood City, CA, USA, ⁴Genomic Health, Inc., Redwood City, CA, USA
- PMD67 M5** *pgA49* **TRENDS IN ONCOLOGY BIOMARKER TESTING IN EUROPE (EU): OBSERVATIONS FROM BREAST CANCER (BC), METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) AND METASTATIC COLORECTAL CANCER (MCRC)**
Narayanan S¹, Butcher A²,¹Ipsos Healthcare, Columbia, MD, USA, ²Ipsos Healthcare, New York, NY, USA
- PMD68 M6** *pgA49* **THE RISE OF THE VALUE ANALYSIS COMMITTEE AT US HOSPITALS, BETTER OR WORSE FOR MEDICAL DEVICE COMPANIES?**
Hristova-Neeley D¹, **Armstrong S**¹, Garfield S¹, Ertel D²,¹GfK Custom Research, Wayland, MA, USA, ²Einstein Healthcare Network, Philadelphia, PA, USA
- PMD69 M7** *pgA50* **ACCESS TO IMPORTED MEDICAL DEVICES DUE TO INFLATION AND UNDER FUNDING OF ARGENTINIAN HEALTH SECTOR IN 2013**
Gilardino R¹, Koffsmo AL¹, Cabra HA²,¹Johnson & Johnson Medical Argentina, Buenos Aires, Argentina, ²Johnson & Johnson Medical, Mexico, D.F., Mexico
- PMD70 M8** *pgA50* **OFFICE-BASED UTERINE POLYPECTOMY USING A MINIMALLY INVASIVE HYSTEROSCOPIC TISSUE REMOVAL DEVICE SAVES HEALTHCARE RESOURCES**
Williams RW¹, **Just PM**², Maxwell A³, McCauley J³,¹Raleigh Gynecology and Wellness, Raleigh, NC, USA, ²Advanced Surgical Devices Division, Smith & Nephew, Inc., Andover, MA, USA, ³Blue Cross and Blue Shield of North Carolina, Durham, NC, USA

- PMD71 M9** *pgA50* **UTILIZATION OF COLORECTAL SCREENING BY MEDICARE BENEFICIARIES IN YEARS 2009 AND 2011: A CROSS-SECTIONAL STUDY**
Sieluk J, Tom S, Stuart B, University of Maryland School of Pharmacy, Baltimore, MD, USA
- PMD72 M10** *pgA50* **BATTLING FEAR: A POTENTIAL KEY TO IMPROVING COLORECTAL CANCER SCREENING**
Qureshi Z¹, Lee MJ², Horner R¹, Bennett C^{3,1}, University of South Carolina, Columbia, SC, USA, ²University of South Carolina, COLUMBIA, SC, USA, ³University of South Carolina College of Pharmacy, Columbia, SC, USA
- PMD73 M11** *pgA50* **HEALTH ECONOMIC MODEL TO MEASURE THE IMPACT OF A STEMI INITIATIVE IN ROMANIA**
Kim E, **Yoculan A**, Medtronic Cardiovascular, Santa Rosa, CA, USA
- PMD74 M12** *pgA50* **EFFECTS OF AUTOLOGOUS FAT GRAFTING SYSTEMS ON INPATIENT OPERATING ROOM TIME AND COSTS: A HOSPITAL BUDGET IMPACT ANALYSIS**
Lee L¹, Xu SJ¹, Mencer M¹, Macarios D¹, Nahabedian MY^{2,1}, LifeCell, an Acelyty Company, Bridgewater, NJ, USA, ²Georgetown University, Washington, DC, USA
- PMD75 M13** *pgA51* **INTEGRATING BIG DATA TO ASSESS THE ECONOMIC IMPACT OF THE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR THERAPY**
Madotto F, Conti S, Chiodini V, Mantovani LG, Fornari C, Cesana G, University of Milano - Bicocca, Monza, Italy
- PMD76 M14** *pgA51* **ECONOMIC AND PATIENT BURDEN OF LIPOHYPERTROPHY IN CHINESE PATIENTS WITH DIABETES**
Chandran A¹, DiMario S¹, Hirsch L¹, Li Q², Sun Z³, Ji L⁴, Qin G⁵, Wei S⁶, Liu J⁶, Luan L⁶, Chapman R⁷, Inocencio T^{8,1}, Becton Dickinson, Franklin Lakes, NJ, USA, ²The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, ³Southeast University Zhongda Hospital, Nanjing, China, ⁴Peking University People's Hospital, Beijing, China, ⁵The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ⁶Becton Dickinson, Beijing, China, ⁷Avalere Health, Washington, DC, USA, ⁸Avalere Health LLC, Washington, DC, USA
- PMD77 M15** *pgA51* **ECONOMIC ANALYSIS OF EVARREST™ COMPARED WITH STANDARD OF CARE IN SOFT TISSUE AND HEPATIC SURGICAL BLEEDING: A U.S. HOSPITAL PERSPECTIVE**
Corral M¹, Ferko N², Hogan A², Hollmann S², Jamous N³, Batiller J¹, Kocharian R^{1,1}, Ethicon Biosurgery, Somerville, NJ, USA, ²Cornerstone Research Group Inc., Burlington, ON, Canada, ³Ethicon Biosurgery, Berkshire, UK
- PMD78 M16** *pgA51* **ECONOMIC IMPACT OF USING HARMONIC SCALPEL TECHNOLOGY IN SURGERY**
Hsiao C, Clymer JW, Cheng H, Ethicon Inc., Cincinnati, OH, USA
- PMD79 M17** *pgA51* **HEMOSTASIS EFFICACY OF EVARREST™ COMPARED TO TACHOSIL® IN LIVER AND OTHER SURGICAL BLEEDING: AN INDIRECT COMPARISON**
Corral M¹, Jamous N², Ferko N³, Bourque M^{3,1}, Ethicon Biosurgery, Somerville, NJ, USA, ²Ethicon Biosurgery, Berkshire, UK, ³Cornerstone Research Group Inc., Burlington, ON, Canada
- PMD80 M18** *pgA52* **EFFECT OF HYDROPHILIC COATING ISOTONIC TO URINE ON INFECTIONS AND COMPLICATIONS AMONG USERS OF INTERMITTENT URINARY CATHETERS**
Neovius K¹, Svensson J¹, Åberg-Håkansson M², Lundqvist T^{2,1}, Aux Analysis, Stockholm, Sweden, ²Wellspect HealthCare, Mölndal, Sweden
- PMD81 N1** *pgA52* **IS THERE UTILITY IN CLINICAL UTILITY MODELING FOR DIAGNOSTIC TECHNOLOGIES?**
Hertz D, Taggart C, Waterman J, Armstrong S, GfK Custom Research, Wayland, MA, USA
- PMD82 N2** *pgA52* **GEOGRAPHIC VARIATION IN DEPRESSION DIAGNOSIS AMONG MEDICARE BENEFICIARIES WITH ACUTE MYOCARDIAL INFARCTION**
Tang Y¹, Kauer J², Schroeder M², Wehby G², Doucette W², Brooks J^{3,1}, Merck, Lebanon, NJ, USA, ²University of Iowa, Iowa City, IA, USA, ³University of South Carolina, Columbia, NJ, USA

DISEASE- SPECIFIC STUDIES

DIABETES/ENDOCRINE DISORDERS - Clinical Outcomes Studies

- PDB1 N3** *pgA52* **URINARY TRACT INFECTION AMONG THE SGLT 2 INHIBITORS: A META-ANALYSIS OF 19 RANDOMIZED CONTROLLED TRIALS**
Gangal NS, Kelton C, Heaton PC, University of Cincinnati, Cincinnati, OH, USA
- PDB2 N4** *pgA52* **STUDY OF PATIENT RELATED OUTCOMES OF TYPE 2 DIABETES AND COMPARATIVE ANALYSIS OF PIOGLITAZONE SALES PRE AND POST BAN IN MUMBAI, INDIA**
Yande S, Hegde P, Velankar K, Dhupal T, Majumdar A, Bombay College Of Pharmacy, Mumbai, India
- PDB3 N5** *pgA52* **COMPARATIVE OUTCOMES OF TESTOSTERONE THERAPY VERSUS NO TREATMENT IN HYPOGONADIC MEN**
Noone J, Blanchette CM, Van Doren BA, Zacherle E, University of North Carolina at Charlotte, Charlotte, NC, USA
- PDB4 N6** *pgA53* **UTILIZATION OF NEGATIVE CONTROLS TO EXAMINE ASSOCIATION BETWEEN RARE GENETIC DISORDERS AND TYPE 2 DIABETES IN FOUR LARGE OBSERVATIONAL DATABASES**
Desai J¹, **Kabadi S²**, St. Louis M², Hyde C², Bonato V³, Loomis K^{2,1}, Pfizer, Inc., New York, NY, USA, ²Pfizer, Inc., Groton, CT, USA, ³Pfizer, Inc., Cambridge, MA, USA
- PDB5 N7** *pgA53* **PREDICTING CHRONIC COMORBID CONDITIONS OF TYPE 2 DIABETES IN NEWLY-DIAGNOSED**

DIABETIC PATIENTS

Razavian N¹, Smith-McLallen A², Nigam S², Blecker S¹, Schmidt AM¹, Sontag D¹,¹New York University, New York City, NY, USA, ²Independence Blue Cross, Philadelphia, PA, USA

- PDB6 N8 pgA53 USING A TREATMENT TRANSITION MODEL TO EVALUATE THE EFFECTS OF NEGLECTING HBA1C DRIFT IN ORAL ANTI-DIABETIC DRUGS FOR TYPE 2 DIABETES**
Smolen HJ, Yu X, Medical Decision Modeling Inc., Indianapolis, IN, USA
- PDB7 N9 pgA53 PREVALENCE AND TIMING OF COMORBID COMPLICATIONS OF TYPE 2 DIABETES IN LARGE COHORT OF INSURANCE SUBSCRIBERS**
Razavian N¹, Smith-McLallen A², Nigam S², Blecker S¹, Schmidt AM¹, Sontag D¹,¹New York University, New York City, NY, USA, ²Independence Blue Cross, Philadelphia, PA, USA
- PDB8 N10 pgA53 ANTI-DIABETIC DRUGS AND THE RISK OF DEMENTIA AMONG MEDICARE BENEFICIARIES WITH DIABETES**
Yuan J, Lu K, University of South Carolina, Columbia, SC, USA
- PDB9 N11 pgA54 PREDICTORS OF GLYCEMIC CONTROL AND DIABETES-RELATED COSTS AMONG ADULT TYPE 2 DIABETES PATIENTS INITIATING THERAPY WITH LIRAGLUTIDE**
Durden E¹, Lenhart G¹, Lopez-Gonzalez L¹, Hammer M², Langer J³,¹Truven Health Analytics, Cambridge, MA, USA, ²Novo Nordisk, Søborg, Denmark, ³Novo Nordisk, Plainsboro, NJ, USA
- PDB10 N12 pgA54 EFFECT OF DAILY OR WEEKLY GLP-1 RECEPTOR AGONISTS ON GLYCEMIC CONTROL IN INSULIN-NAÏVE PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES: A REAL-WORLD STUDY**
Singhal M¹, Nguyen H², Schauerhamer M¹, Unni S¹, Cobden D³, McAdam-Marx C¹,¹University of Utah, Salt Lake City, UT, USA, ²AstraZeneca, Fort Washington, PA, USA, ³AstraZeneca, Saratoga, NY, USA
- PDB11 N13 pgA54 IDEGLIRA VERSUS OTHER INTENSIFICATION STRATEGIES IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN – AN INDIRECT STATISTICAL COMPARISON**
Freemantle N¹, Mamdani M², Vilsbøll T³, Kongsø JH⁴, Kvist K⁵, Bain SC⁶,¹University College London, London, UK, ²University of Toronto and St. Michael's Hospital, Toronto, ON, Canada, ³Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, ⁴Novo Nordisk A/S, Bagsvaerd, Denmark, ⁵Novo Nordisk A/S, Søborg, Denmark, ⁶Institute of Life Sciences, Swansea University, Swansea, UK
- PDB12 N14 pgA54 BAYESIAN NETWORK META-ANALYSIS (NMA) TO ASSESS RELATIVE EFFICACY OF CANAGLIFLOZIN (CANA) VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN DUAL AND TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)**
Van Sanden S¹, Diels J¹, Guillon P², Nielsen AT³,¹Janssen Research & Development, Beerse, Belgium, ²Janssen-Cilag France, Issy-les-Moulineaux, Cedex, France, ³Janssen-Cilag A/S, Birkerød, Denmark
- PDB13 N15 pgA54 REAL-WORLD CANAGLIFLOZIN UTILIZATION: IMPACT ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS**
Meckley LM¹, Miyasato G¹, Kokkotos F¹, Bailey RA²,¹Trinity Partners, LLC, Waltham, MA, USA, ²Janssen Scientific Affairs, LLC, Raritan, NJ, USA
- PDB14 N16 pgA55 EFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON HEMOGLOBIN A1C IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND RENAL IMPAIRMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Singh-Franco D¹, Harrington C², Tellez-Corrales E³,¹Nova Southeastern University, Fort Lauderdale, FL, USA, ²Nova Southeastern University, Palm Beach Gardens, FL, USA, ³Pacific Oaks Medical Plaza, Beverly Hills, CA, USA
- PDB15 N17 pgA55 COMPARATIVE EFFICACY AND SAFETY OF ANTIDIABETIC DRUG REGIMENS ADDED TO STABLE AND INADEQUATE METFORMIN AND THIAZOLIDINEDIONE THERAPY IN TYPE 2 DIABETES**
Saulsberry WJ¹, Mearns ES¹, Zaccaro E¹, Doleh Y¹, Coleman CI²,¹University of Connecticut, Storrs, CT, USA, ²University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, CT, USA
- PDB16 N18 pgA55 REAL-WORLD TREATMENT PATTERNS OF ANTIHYPERGLYCEMIC AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATED ON CANAGLIFLOZIN**
Chow W¹, Buysman EK², Rupnow MF¹, Henk HJ²,¹Janssen Scientific Affairs, LLC, Raritan, NJ, USA, ²Optum, Eden Prairie, MN, USA
- PDB17 O1 pgA55 TIME UNTIL INSULIN INITIATION FOR CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN DUAL AND TRIPLE THERAPY FOR TYPE 2 DIABETES MELLITUS (T2DM) IN IRELAND**
Bacon T¹, Willis M², Johansen P², Neslusan C³,¹Janssen-Cilag Ltd, Dublin, Ireland, ²The Swedish Institute for Health Economics, Lund, Sweden, ³Janssen Global Services, LLC, Raritan, NJ, USA
- PDB18 O2 pgA55 EFFICACY AND SAFETY OF INSULIN ANALOGUES COMPARED TO HUMAN INSULIN PREPARATIONS FOR THE TREATMENT OF PATIENTS WITH DIABETES TYPE 1 (DM1): SYSTEMATIC REVIEW AND META-ANALYSIS**
Guerra-Junior Aa¹, Araujo VE¹, Izidoro JB¹, Diniz LM², Silva MR¹, Mata AR¹, Nascimento RC¹, Alvares J¹, Acurcio Fa¹,¹College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, ²Medical College, Federal University of Minas Gerais, Belo Horizonte, Brazil
- PDB19 O3 pgA55 METFORMIN AND INTENSIVE LIFESTYLE INTERVENTION FOR PRE-DIABETES - SYSTEMATIC REVIEW OF EFFICACY**

Fujii RK¹, Junqueira M¹, Restrepo M², Turatti LA^{3,1}, Merck Serono, São Paulo, Brazil, ²Merck Serono, Bogota, Colombia, ³FMUSP, São Paulo, Brazil

PDB20 O4 pgA56 EFFICACY AND SAFETY OF AN EXTENDED-RELEASE METFORMIN FORMULATION IN TYPE-2 DIABETES MELLITUS TREATMENT: A SYSTEMATIC REVIEW

Fujii RK¹, Restrepo M², Fernandes RA³, Haas L⁴, Pepe C³, Turatti LA⁵, Junqueira M¹, ¹Merck Serono, São Paulo, Brazil, ²Merck Serono, Bogota, Colombia, ³Grupo Resulta, São Paulo, Brazil, ⁴ANOVA, Rio de Janeiro, Brazil, ⁵FMUSP, São Paulo, Brazil

PDB21 O5 pgA56 A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF ANTI-DIABETES TREATMENTS FOR ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON INSULIN AND ORAL ANTI-DIABETES DRUGS

Orme M¹, Mukherjee J², Sternhufvud C³, Smith N⁴, Fenici P⁵, ¹ICERA Consulting Ltd, Swindon, UK, ²Bristol Myers Squibb, Wallingford, CT, USA, ³AstraZeneca, Mölndal, Sweden, ⁴Bristol Myers Squibb, Lawrenceville, NJ, USA, ⁵AstraZeneca, Melbourn Hertfordshire, UK

PDB22 O6 pgA56 BAYESIAN NETWORK META-ANALYSIS (NMA) TO ASSESS THE RELATIVE EFFICACY OF CANAGLIFLOZIN MONOTHERAPY OVER 26 WEEKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

Schroeder M¹, Taieb V², Belhadi D², Seyla-Hammer C², Hemels M³, Nielsen AT³, ¹Janssen-Cilag UK, High Wycombe, UK, ²Amaris London, London, UK, ³Janssen-Cilag A/S, Birkerød, Denmark

PDB23 O7 pgA56 CLINICAL EVALUATION OF SHUDDHA GUGGULU IN HYPOTHYROIDISM PATIENTS

Suvarna HP¹, Acharya S², Nagappa AN³, ¹Muniyal College of Ayurveda, Manipal, India, ²Muniyal Institute of Ayurveda Medical sciences, Manipal, India, ³Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India

PDB24 O8 pgA56 EFFICACY AND SAFETY OF CANAGLIFLOZIN AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Kaur K¹, Likhar N², Dang A², ¹Dayanand Medical College & Hospital, Ludhiana, India, ²MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

PDB25 O9 pgA57 ANTI-DIABETIC THERAPIES AND THE RISK OF ACUTE PANCREATITIS: A NATIONWIDE RETROSPECTIVE COHORT STUDY FROM TAIWAN

Chiang Y¹, Chang H², Hsieh C¹, Singh S³, Tang W⁴, Tasi Y¹, Huang W⁵, ¹National Yang-Ming University, Taipei, Taiwan, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ³Johns Hopkins Medicine, Baltimore, MD, USA, ⁴The George Washington University, Washington, DC, USA, ⁵National Yang Ming University, Taipei, Taiwan

PDB26 P1 pgA57 REAL-WORLD ADHERENCE IN MEDICARE PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOR EXENATIDE QW AND LIRAGLUTIDE QD

Tarr A¹, Nguyen H², Dufour R¹, Bullano M², ¹Comprehensive Health Insights, Inc, Louisville, KY, USA, ²AstraZeneca, Fort Washington, PA, USA

PDB27 P2 pgA57 GLYCATED HEMOGLOBIN (HBA1C) CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) TREATED WITH CANAGLIFLOZIN IN A REAL-WORLD SETTING

Lefebvre P¹, Pilon D², Robitaille M¹, Lafeuille M¹, Chow W³, Pfeifer M³, Duh MS⁴, ¹Groupe d'analyse, Itée, Montreal, QC, Canada, ²Groupe d'analyse, Ltée, Montreal, QC, Canada, ³Janssen Scientific Affairs, LLC, Raritan, NJ, USA, ⁴Analysis Group, Boston, MA, USA

PDB28 P3 pgA57 PATTERNS OF TREATMENT ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING LINAGLIPTIN AND OTHER NON-INSULIN DIABETES MEDICATIONS (NIDMS)

Paterno E¹, Gopalakrishnan C¹, Zorina O², Schneeweiss S¹, Bartels D², Seeger JD¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, ²Boehringer Ingelheim GmbH, Ingelheim, Germany

PDB29 P4 pgA57 THE EFFECT OF RAS-MODIFYING MEDICATIONS ON PULMONARY HEALTH IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Bang SI, Soto M, Rodgers K, McCombs J, ¹University of Southern California, Los Angeles, CA, USA

PDB30 P5 pgA57 TEMPORAL TREND AND PREVALENCE OF CKD STAGES (KDIGO 2012) IN US ADULTS WITH TYPE 2 DIABETES MELLITUS AND DEMOGRAPHIC SUBGROUPS: NHANES 2007-2012

Wu B¹, Bell K², Kern DM¹, Tunceli O³, Willey V¹, Vupputuri S¹, Stanford A⁴, Kalsekar I⁵, ¹HealthCore Inc, Wilmington, DE, USA, ²AstraZeneca, Fort Washington, PA, USA, ³HealthCore, Inc., Wilmington, DE, USA, ⁴Bristol-Myers Squibb Company, Plainsboro, NJ, USA, ⁵AstraZeneca, Wilmington, DE, USA

PDB31 P6 pgA58 COMPARISON OF REAL-WORLD HYPOGLYCEMIA RATES AMONG PATIENTS INITIATING TREATMENT WITH SAXAGLIPTIN OR GLIPIZIDE

Johnston S¹, Bell K², Thomson E³, Lenhart G³, Sheehan J², ¹Truven Health Analytics, Bethesda, MD, USA, ²AstraZeneca, Fort Washington, PA, USA, ³Truven Health Analytics, Cambridge, MA, USA

PDB32 P7 pgA58 ASSOCIATION BETWEEN BONE MINERAL DENSITY AND TYPE 1 DIABETES MELLITUS: A META-ANALYSIS OF OBSERVATIONAL STUDIES

Shah Cs¹, Shah VN², Likhar N³, Mothe RK³, Kanukula R³, Dang A³, ¹SJM college of pharmacy, chitradurga, India, ²University of Colorado, Colorado, CO, USA, ³MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

PDB34 P8 pgA58 CHANGES IN THE SAFETY PROFILE OF ORAL DIABETES MEDICATIONS APPROVED BY THE FDA
Al-Mutairi R, Seoane-Vazquez E, MCPHS University, Boston, MA, USA

DIABETES/ENDOCRINE DISORDERS - Cost Studies

PDB35 P9 pgA58 MODELING THE LONG TERM ECONOMIC BENEFITS OF A PATIENT-ADJUSTED MEALTIME INSULIN TITRATION ALGORITHM AMONG PATIENTS WITH TYPE 2 DIABETES IN THE UNITED STATES
Numapau NO¹, Murphy DR², Curtis BH¹, Gahn JC², Curtis S¹, Perk S², Yu X², Smolen HJ^{2,1}, Eli Lilly, Indianapolis, IN, USA, ²Medical Decision Modeling Inc., Indianapolis, IN, USA

PDB36 Q1 pgA59 COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT OF AN EXTENDED VERSUS IMMEDIATE RELEASE FORMULATION OF METFORMIN IN TYPE-2 DIABETES MELLITUS TREATMENT, FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
Fujii RK¹, Restrepo M², Fernandes RA³, Haas L⁴, Pepe C³, Junqueira M¹, ¹Merck Serono, São Paulo, Brazil, ²Merck Serono, Bogota, Colombia, ³Grupo Resulta, São Paulo, Brazil, ⁴ANOVA, Rio de Janeiro, Brazil

PDB37 Q2 pgA59 DIRECT MEDICAL COSTS ASSOCIATED WITH DIABETIC COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES IN THE US VERSUS SOUTH KOREA
Chang C¹, Lee S¹, Kim C², Suh D¹, ¹Chung-Ang University, Seoul, South Korea, ²Catholic University College of Medicine, Seoul, South Korea

PDB39 Q3 pgA59 ECONOMIC IMPACT OF DAPAGLIFLOZIN VS. OTHER ANTIDIABETIC DRUGS FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
Lin J¹, Dhankhar P², Bell K², Chhatwal J³, Lingohr-Smith M¹, ¹Novosys Health, Green Brook, NJ, USA, ²AstraZeneca, Fort Washington, PA, USA, ³The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PDB40 Q4 pgA59 EVALUATION OF THE ANNUAL COST OF MEDICINES USED IN TREATMENT OF TYPE 2 DIABETES MELLITUS IN INDIA
Hussain S, Kumari S, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India

PDB41 Q5 pgA59 ECONOMIC BURDEN AND POOR QUALITY OF LIFE ASSOCIATED WITH ACROMEGALY IN THE UNITED STATES
Liu S¹, Xu Y², Sisco J³, Begelman SM², Shi L⁴, ¹Tulane University, NEW ORLEANS, LA, USA, ²Genentech Inc., South San Francisco, CA, USA, ³Acromegaly Community, Grove, OK, USA, ⁴Tulane University, New Orleans, LA, USA

PDB42 Q6 pgA59 ESTIMATING CLINICAL AND ECONOMIC OUTCOMES FOLLOWING A DIABETES-RELATED VASCULAR COMPLICATION
Perk S¹, Murphy DR², Gahn JC², Yu X², **Smolen HJ**^{2,1}, Medical Decision Modeling, Indianapolis, IN, USA, ²Medical Decision Modeling Inc., Indianapolis, IN, USA

PDB43 Q7 pgA60 ECONOMIC BENEFITS OF ULTRASONIC DEVICES IN THYROIDECTOMY
Hsiao C¹, Cheng H¹, Tao C², Chawla AS³, Faulkner EC⁴, DeRamus S⁵, ¹Ethicon Inc., Cincinnati, OH, USA, ²Quintiles Consulting, Cambridge, MA, USA, ³Quintiles Consulting, Durham, NC, USA, ⁴Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA, ⁵Johnson and Johnson Medical Companies, Cincinnati, OH, USA

PDB44 Q8 pgA60 HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG DIABETES PATIENTS RESIDING IN LONG-TERM CARE FACILITIES
Huang A¹, Shrestha S¹, Baser O², Yuce H³, Wang L¹, ¹STATinMED Research, Plano, TX, USA, ²STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, ³City University of New York & STATinMED Research, New York, NY, USA

PDB45 Q9 pgA60 THE CLINICAL AND ECONOMIC VALUE OF A DIGITAL LIFESTYLE INTERVENTION PROGRAM IN THE PREDIABETES POPULATION: CASE STUDY WITH THE 'PREVENT' PROGRAM
Su W¹, Dall T¹, Chen F², Iacobucci W¹, Su K³, ¹IHS Life Sciences, Washington, DC, USA, ²IHS Inc., Washington, DC, USA, ³Omada Health, San Francisco, CA, USA

PDB46 R1 pgA60 A HEALTH ECONOMIC EVALUATION OF THE EDGE STUDY USING THE IMS CORE DIABETES MODEL
McEwan P¹, Evans M², Foos V³, Paldánus PM⁴, ¹Health Economics and Outcomes Research Ltd, Monmouth, UK, ²University Hospital Llandough, Cardiff, UK, ³IMS Health, Basel, Switzerland, ⁴Novartis Pharma AG, Basel, Switzerland

PDB47 R2 pgA60 DIABETES MELLITUS TREATMENT: COST-EFFECTIVENESS OF SCHEMES THERAPEUTIC GLARGINE AND NPH - BRAZIL, 2014
Alvares J¹, Almeida AM², Faleiros D¹, Araujo VE¹, Guerra Junior AA¹, Acúrcio Fd¹, ¹College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, ²Federal University of Minas Gerais, Belo Horizonte, Brazil

PDB48 R3 pgA61 THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
Sabapathy S¹, Neslusan C², Yoong K¹, Teschemaker AR², Johansen P³, Willis M³, ¹Janssen Inc, Toronto, ON, Canada, ²Janssen Global Services, LLC, Raritan, NJ, USA, ³The Swedish Institute for Health Economics, Lund, Sweden

- PDB49 R4** *pgA61* **A COST-EFFECTIVENESS ANALYSIS OF ALOGLIPTIN IN COMPARISON TO SAXAGLIPTIN**
Wingate LT, Oishi TS, Shubar Ali NS, Howard University, Washington, DC, USA
- PDB50 R5** *pgA61* **THE COST-EFFECTIVENESS EVALUATION OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN MONOTHERAPY IN SPAIN**
Nielsen AT¹, Pitcher A², Lovato E², **Schubert A**³, Hemels M¹, Neslusan C⁴, González B⁵,¹Janssen-Cilag A/S, Birkerød, Denmark, ²IMS Health, London, UK, ³Janssen-Cilag Poland, Warsaw, Poland, ⁴Janssen Global Services, LLC, Raritan, NJ, USA, ⁵Janssen-Cilag Spain, Madrid, Spain
- PDB51 R6** *pgA61* **A COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN COMPARISON TO DIPEPTIDYL PEPPTIDASE 4-INHIBITORS USING A META-ANALYSIS**
Oishi TS, Shubar Ali NS, Wingate LT, Howard University, Washington, DC, USA
- PDB52 R7** *pgA61* **COST-EFFECTIVENESS (CE) ANALYSIS OF EMPAGLIFLOZIN 25MG VERSUS SITAGLIPTIN 100MG IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WHEN ADDED TO METFORMIN (MET) FROM A MEXICAN PUBLIC INSTITUTIONAL CONTEXT**
Huicochea-Bartelt JL¹, Vargas-Valencia JJ², Herran S¹,¹Boehringer Ingelheim, Distrito Federal, Mexico, ²Econopharma Consulting, -, Mexico
- PDB53 R8** *pgA61* **COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE AND THIRD-LINE ANTIDIABETIC DRUGS IN TYEP 2 DIABETES: AN EMPIRICAL, POPULATION-BASED OBSERVATIONAL STUDY FROM TAIWAN**
Ou H¹, **Balkrishnan R**², Yang C¹, Chang K¹,¹National Cheng Kung University, Tainan, Taiwan, ²University of Michigan, Ann Arbor, MI, USA
- PDB54 R9** *pgA62* **IMPACT OF WEIGHT-RELATED UTILITIES ON THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING**
Sabapathy S¹, Neslusan C², Yoong K¹, Teschemaker AR², Johansen P³, Willis M³,¹Janssen Inc, Toronto, ON, Canada, ²Janssen Global Services, LLC, Raritan, NJ, USA, ³The Swedish Institute for Health Economics, Lund, Sweden
- PDB55 S1** *pgA62* **THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS AN ADD-ON TO METFORMIN OR METFORMIN PLUS SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN**
Nielsen AT¹, Pitcher A², Lovato E², **Schubert A**³, Hemels M¹, Neslusan C⁴, González B⁵,¹Janssen-Cilag A/S, Birkerød, Denmark, ²IMS Health, London, UK, ³Janssen-Cilag Poland, Warsaw, Poland, ⁴Janssen Global Services, LLC, Raritan, NJ, USA, ⁵Janssen-Cilag Spain, Madrid, Spain
- PDB56 S2** *pgA62* **LIRAGLUTIDE VS. SITAGLIPTIN AS ADD-ON TO METFORMIN TREATMENT FOR TYPE 2 DIABETES MELLITUS: SHORT TERM COST-PER-CONTROLLED PATIENT IN ITALY**
Ramirez de Arellano A¹, Montagnoli R², Ferrario MG³,¹Novo Nordisk, Madrid, Spain, ²Novo Nordisk, Rome, Italy, ³Outcomes'10, Castellon, Spain
- PDB57 S3** *pgA62* **THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)**
Willis M¹, Johansen P¹, **Neslusan C**²,¹The Swedish Institute for Health Economics, Lund, Sweden, ²Janssen Global Services, LLC, Raritan, NJ, USA
- PDB58 S4** *pgA62* **THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA**
Teschemaker AR¹, Neslusan C¹, Sabapathy S², Yoong K², Johansen P³, Willis M³,¹Janssen Global Services, LLC, Raritan, NJ, USA, ²Janssen Inc, Toronto, ON, Canada, ³The Swedish Institute for Health Economics, Lund, Sweden
- PDB59 S5** *pgA63* **EVALUATING THE COST OF BRINGING PEOPLE WITH TYPE 2 DIABETES MELLITUS TO MULTIPLE TARGETS OF TREATMENT IN CANADA**
Skovgaard R¹, Ploug UJ², Hunt B³, Valentine WJ³,¹Novo Nordisk Canada Inc., Mississauga, ON, Canada, ²Novo Nordisk A/S, Søborg, Denmark, ³Ossian Health Economics and Communications, Basel, Switzerland
- PDB60 S6** *pgA63* **COST EFFECTIVENES ANALYSIS OF DPP4 INHIBITORS**
Jimenez-Aranda P¹, Perez Bolde-Villarreal C¹, Pastor-Martinez V¹, Guarin D²,¹Merck Sharp & Dohme, Mexico, Mexico, ²Merck Sharp & Dohme, Bogotá, Colombia
- PDB61 S7** *pgA63* **PHARMACOECONOMIC EVALUATION OF GLP-1 RECEPTORS AGONIST VERSUS DPP-4 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES : A SYSTEMATIC REVIEW**
Long E¹, Fang Y², **Hu M**², Zhou N²,¹Sichuan Provincial People' s Hospital, Chengdu, China, ²Sichuan University, Chengdu, China
- PDB62 S8** *pgA63* **DETEMIR IN DIABETES TYPE 2 PATIENTS A COST-UTILITY ANALYSIS, COLOMBIA 2014**
Romero M¹, Huerfano LM², Paez ML³, Acero G⁴,¹PhD (c) Public Health, National University of Colombia., Bogota, Colombia, ²Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, ³Salutia's Foundation- Research center in economy, management and health technologies., Bogota, Colombia, ⁴Salutia Foundation- Research center in economy, management and health technologies., Bogota,

Colombia

- PDB63 S9** *pgA63* **PREVALENCE AND TREATMENT OF GENITOURINARY CONDITIONS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS**
Gries K¹, **Cai B**², Yu R³, Kuti E², Sander S², Hareendran A⁴,¹Evidera, Seattle, WA, USA, ²Boehringer Ingelheim, Ridgefield, CT, USA, ³Evidera, Bethesda, MD, USA, ⁴Evidera, Inc., London, UK

DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PDB64 T1** *pgA63* **IMPACT OF A PHARMACIST TELEPHONE INTERVENTION ON PREVENTING MEDICATION DISCONTINUATION AMONG HYPERTENSIVE PATIENTS WITH DIABETES IN A MEDICARE ADVANTAGE PLAN**
Wang X¹, Serna O², Henges C², Essien EJ¹, Chung N³, Fleming M¹, Abughosh S¹,¹University of Houston, Houston, TX, USA, ²Cigna HealthSpring, Houston, TX, USA, ³U of Houston, Houston, TX, USA
- PDB65 T2** *pgA64* **DIABETES EDUCATION: PATTERNS AND IMPACT ON MEDICATION ADHERENCE**
Noxon V¹, Davis-Ajami ML², Lu K¹, Wu J¹,¹University of South Carolina, Columbia, SC, USA, ²Virginia Commonwealth University, Richmond, VA, USA
- PDB66 T3** *pgA64* **IMPACT OF A PHARMACIST TELEPHONE INTERVENTION ON MEDICATION ADHERENCE AMONG HYPERTENSIVE PATIENTS WITH DIABETES IN A MEDICARE ADVANTAGE PLAN**
Abughosh S¹, Wang X¹, Serna O², Henges C², Essien EJ¹, Masilamani S³, Fleming M¹,¹University of Houston, Houston, TX, USA, ²Cigna HealthSpring, Houston, TX, USA, ³U of Houston, Houston, TX, USA
- PDB67 T4** *pgA64* **ADHERENCE TO LIRAGLUTIDE ONCE DAILY OR EXENATIDE ONCE WEEKLY OVER A 12-MONTH PERIOD AMONG COMMERCIALY INSURED PATIENTS WITH TYPE 2 DIABETES MELLITUS: A RETROSPECTIVE OBSERVATIONAL STUDY**
Johnston S¹, Nguyen H², Cappell KA³, Nelson J³, Chu B³, Kalsekar I⁴,¹Truven Health Analytics, Bethesda, MD, USA, ²AstraZeneca, Fort Washington, UT, USA, ³Truven Health Analytics, Ann Arbor, MI, USA, ⁴AstraZeneca, Wilmington, DE, USA
- PDB68 T5** *pgA64* **BARRIERS TO TREATMENT ADHERENCE ASSOCIATED WITH ACROMEGALY IN THE UNITED STATES: PROVIDER'S PERSPECTIVE**
Liu S¹, Xu Y², Begelman SM², Shi L³,¹Tulane University, NEW ORLEANS, LA, USA, ²Genentech Inc., South San Francisco, CA, USA, ³Tulane University, New Orleans, LA, USA
- PDB69 T6** *pgA64* **VALIDATION OF PRESCRIPTION MEDICATION ADHERENCE PREDICTION TOOL (RXAPT) TO PREDICT NON-ADHERENCE AMONG DIABETES PATIENTS ENROLLED IN MEDICARE**
Mhatre SK¹, Sangsiry S², Serna O³, Sangsiry SS¹,¹University of Houston, Houston, TX, USA, ²VA Medical Center, Houston, TX, USA, ³Cigna HealthSpring, Houston, TX, USA
- PDB70 T7** *pgA65* **THE RELATIONSHIP BETWEEN OUTCOMES IN TYPE 2 DIABETES AND ADHERENCE AS MEASURED BY THE MORISKY ADHERENCE SCALES**
Pedersini R¹, Vietri J²,¹Kantar Health, Epsom, UK, ²Kantar Health, Horsham, PA, USA
- PDB71 T8** *pgA65* **INVESTIGATING THE SHORT-TERM IMPACT OF POOR GLYCEMIC CONTROL ON THE DAILY LIVES OF PEOPLE WITH TYPE 2 DIABETES**
Jendle J¹, Ridderstråle M², Jensen HH³, Bøgelund M³, **Jensen MM**⁴, Ericsson A⁵, Evans M⁶,¹Örebro University, Örebro, Denmark, ²Steno Diabetes Center, Gentofte, Denmark, ³Incentive, Holte, Denmark, ⁴Novo Nordisk, Copenhagen, Denmark, ⁵Novo Nordisk Scandinavia AB, Malmö, Sweden, ⁶University Hospital Llandough, Cardiff, UK
- PDB72 T9** *pgA65* **INFLUENCE OF PATIENT-REPORTED OUTCOMES ON REGULATORY, HTA AND MARKET ACCESS DECISIONS: OBESITY AND DIABETES CASE EXAMPLES**
Doward L¹, Højbjerg L², DeMuro C³, Hogue S³, Fernandez M³, Barrett A³, Crawford SR¹, Kragh N², Aagren M²,¹RTI Health Solutions, Manchester, UK, ²Novo Nordisk A/S, Søborg, Denmark, ³RTI Health Solutions, Research Triangle Park, NC, USA
- PDB73 U1** *pgA65* **LOW TREATMENT SATISFACTION ASSOCIATED WITH ACROMEGALY IN THE UNITED STATES**
Liu S¹, Xu Y², Sisco J³, Begelman SM², Shi L⁴,¹Tulane University, NEW ORLEANS, LA, USA, ²Genentech Inc., South San Francisco, CA, USA, ³Acromegaly Community, Grove, OK, USA, ⁴Tulane University, New Orleans, LA, USA
- PDB74 U2** *pgA65* **ASSESSMENT OF DIETRY KNOWLEDGE, MYTHS AND MISCONCEPTIONS AMONG DIABETIC PATIENTS**
ul Hag N¹, Akbar N¹, Iqbal Q¹, Naseem A¹, Azhar SA², Bashir S³,¹University of Balochistan, Quetta, Pakistan, ²COMSATS Institute of Information Technology, Abbottabad, Pakistan, ³University of Sargodha, Sargodha, Pakistan
- PDB75 U3** *pgA65* **ENGAGING PATIENTS WITH E-CLINICAL TECHNOLOGY: INCORPORATING PATIENT PREFERENCES INTO DIABETES CLINICAL TRIALS AND CARE**
Khurana L¹, **Gary ST**¹, Vazquez V¹, Otero A¹, Evans C², Dallabrida S¹,¹PHT Corporation, Boston, MA, USA, ²Endpoint Outcomes, Boston, MA, USA
- PDB76 U4** *pgA66* **PATIENT'S AND PROFESSIONAL'S PREFERENCES FOR TYPE 2 DIABETES MELLITUS TREATMENTS (T2DM) IN SPAIN AND PORTUGAL. A DISCRETE CHOICE EXPERIMENT**
Morillas C¹, Feliciano R², Fernandez Catalina P³, Ponte C⁴, Botella M⁵, Rodrigues J⁶, Esmatjes E⁷, Lafita J⁸, Lizan

L⁹, Llorente I¹⁰, Morales C¹¹, Navarro J¹², Orozco D¹³, Paz S⁹, Tribaldos de Suarez M⁹, **Ramirez de Arellano A**¹⁴, Cardoso C¹⁵, ¹Hospital Universitario Doctor Peset, Valencia, Spain, ²USF Sao Domingos, Santarém, Portugal, ³Hospital Montecelo, Pontevedra, Spain, ⁴USF Porta Do Sol, Matosinhos, Portugal, ⁵Hospital Univeristario Principe de Asturias, Madrid, Spain, ⁶USF Serra da Lousa, Lousa, Portugal, ⁷Hospital Clinic, Barcelona, Spain, ⁸Hospital de Navarra, Pamplona, Spain, ⁹Outcomes 10, Castellon, Spain, ¹⁰Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, ¹¹Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ¹²Centro de Salud Salvador Pau, Valencia, Spain, ¹³Sociedad Española de Medicina Familiar y Comunitaria, Barcelona, Spain, ¹⁴Novo Nordisk, Madrid, Spain, ¹⁵Novo Nordisk Lisbon, Paço de Arcos, Portugal

PDB77 U5 pgA66 DEFINING UNCONTROLLED DIABETES FROM THE PATIENT PERSPECTIVE: A FOUR-COUNTRY STUDY IN PEOPLE WITH TYPE-2 DIABETES ON BASAL INSULIN

Brod M¹, Fisher C¹, Barnett AH², Berntorp K³, Vilsbøll T⁴, Weissenberger B⁵, ¹The Brod Group, Mill Valley, CA, USA, ²Birmingham Heartlands Hospital, Birmingham, UK, ³Lund Univerity, Department of Endocrinology, Skane University Hospital, Malmo, Sweden, ⁴Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, ⁵FMH Endokrinologie und Diabetologie, Basel, Switzerland

PDB78 U6 pgA66 ANALYZING EQ-5D IN PHASE 3 CLINICAL TRIALS OF TYPE 2 DIABETES MELLITUS (T2DM): IS MEAN CHANGE CAPTURING PATIENT IMPACT?

Slee A¹, Traina S², Neslusan C², ¹Axio Research, Seattle, WA, USA, ²Janssen Global Services, LLC, Raritan, NJ, USA

PDB79 U7 pgA66 ANALYSIS OF METABOLIC SYNDROME PATIENTS' SELF-REPORTED MEDICATION ADHERENCE BARRIERS AFFECT ON PILL COUNT

Brinkerhoff AJ, Pinto S, Bechtol R, ¹University of Toledo, Toledo, OH, USA

PDB80 V1 pgA66 GROWTH HORMONE DEFICIENCY IN PEDIATRICS: CONCEPT ELICITATION TO SUPPORT THE DEVELOPMENT OF CHILD PRO AND PARENT OBSRO MEASURES

Brod M¹, Håkan-Bloch J², Hojbjerg L², Alolga SL¹, Nacson A¹, Rasmussen MH², ¹The Brod Group, Mill Valley, CA, USA, ²Novo Nordisk A/S, Søborg, Denmark

PDB81 V2 pgA67 PATIENT REPORTED OUTCOME PROFILES OF ADULTS RECEIVING MEDICAL CARE AT SPECIALTY CLINICS FOR CHRONIC PAIN AND DIABETES

Amtmann D¹, Patel KV¹, Bacci ED², Bamer AM¹, Turk DC¹, ¹University of Washington, Seattle, WA, USA, ²Evidera, Seattle, WA, USA

PDB82 V3 pgA67 UTILIZING THE SF-36V2 MENTAL COMPONENT SUMMARY SCORE TO DESCRIBE MENTAL WELL-BEING EXPERIENCED BY PATIENTS WITH TYPE 2 DIABETES

Bolge SC¹, Flores NM², Phan J¹, ¹Janssen Scientific Affairs, LLC, Raritan, NJ, USA, ²Kantar Health, Foster City, CA, USA

PDB83 V4 pgA67 THE INCREMENTAL BURDEN OF OBESITY AND SLEEP DISORDERS AMONG INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS

Gupta S¹, Wang Z², Flores NM³, ¹Kantar Health, Princeton, NJ, USA, ²Eisai Inc., Woodcliff Lake, NJ, USA, ³Kantar Health, Foster City, CA, USA

PDB84 V5 pgA67 IMPACT OF DEPRESSION ON ABC GOAL ATTAINMENT & HEALTH-RELATED QUALITY OF LIFE AMONG ADULTS WITH TYPE 2 DIABETES

Shah BM¹, **Mezzio D**², Ho J¹, Ip E¹, ¹Touro University California, Vallejo, CA, USA, ²Touro University California, Davis, CA, USA

PDB85 V6 pgA67 AN INDIRECT COMPARISON OF IWQOL-LITE TOTAL SCORE CHANGE IN SUBJECTS TREATED WITH CANAGLIFLOZIN, EXENATIDE QW, SITAGLIPTIN, OR PIOGLITAZONE IN DUAL THERAPY WITH BACKGROUND METFORMIN

Traina S¹, **Slee A**², Van Sanden S³, Diels J³, ¹Janssen Global Services, LLC, Raritan, NJ, USA, ²Axio Research, Seattle, WA, USA, ³Janssen Research & Development, Beerse, Belgium

PDB86 V7 pgA67 DEPRESSION TREATMENT AND HEALTH-RELATED QUALITY OF LIFE AMONG ADULTS WITH DIABETES AND DEPRESSION

Alenzi E, Sambamoorthi U, ¹West Virginia University, Morgantown, WV, USA

DIABETES/ENDOCRINE DISORDERS - Health Care Use & Policy Studies

PDB87 W1 pgA68 PATIENT BENEFIT-RISK PREFERENCE OF INSULIN TREATMENT: AN EXAMINATION OF HEALTH LITERACY- AND BELIEFS AS PREDICTORS OF PREFERENCE AND RISK AVERSION


von Arx L, ¹University of Southern Denmark, Odense, Denmark

PDB88 W2 pgA68 PRESCRIBING PATTERN, GUIDELINE ADHERENCE AND DIABETES MELLITUS MANAGEMENT WITH CO-MORBIDITIES: A MALAYSIAN HOSPITAL PERSPECTIVE

Iqbal MZ¹, Khan AH², Sulaiman SA², Iqbal MS³, Iqbal MW⁴, ¹Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia, ²Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, ³Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia, ⁴Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, ⁵Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia

- PDB89 W3 pgA68 A MULTIVARIATE ANALYSIS OF PRESCRIBING INFORMATION FOR NEXT GENERATION TYPE 2 DIABETES TREATMENTS**
Taylor D, Martin S, Sjostedt P, The Medicine Group, New Hope, PA, USA
- PDB90 W4 pgA68 MEDICATION UTILIZATION PATTERN FOR PAIN MANAGEMENT AMONG INDIVIDUALS WITH TYPE 2 DIABETES**
Atreja N, Fleming M, University of Houston, Houston, TX, USA
- PDB91 W5 pgA68 COMPARATIVE PERSISTENCY WITH NEWER AGENTS USED TO TREAT TYPE 2 DIABETES (T2DM) IN THE UNITED STATES: CANAGLIFLOZIN VERSUS DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS**
Diels J¹, Neslusan C²,¹Janssen Research & Development, Beerse, Belgium, ²Janssen Global Services, LLC, Raritan, NJ, USA
- PDB92 W6 pgA69 CURRENT REAL-WORLD PRESCRIBING PATTERNS IN TYPE 2 DIABETES MELLITUS: WHAT COMES AFTER METFORMIN? EVIDENCE FROM U.S. INTEGRATED DELIVERY NETWORKS**
Apfelbaum L¹, Iorga SR², McDonald M², Liu L², Piper BA², Sollano J²,¹University of Pennsylvania, Philadelphia, PA, USA, ²Pfizer Inc., New York, NY, USA
- PDB93 W7 pgA69 DOES TREATMENT FOR NEWLY-DIAGNOSED DEPRESSION REDUCE HEALTHCARE EXPENDITURES AMONG MEDICAID BENEFICIARIES WITH TYPE 2 DIABETES MELLITUS?**
Bhattacharya R¹, Wachholtz A², Dwibedi N³, Misra R³, Scott V³, Sambamoorthi U³,¹West Virginia University, Tucson, AZ, USA, ²University of Massachusetts, North Worcester, MA, USA, ³West Virginia University, Morgantown, WV, USA
- PDB94 W8 pgA69 EVOLUTION OF THE MARKET FOR ORAL ANTIDIABETIC AGENTS IN CANADA AFTER INTRODUCTION OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS**
Lavoie L, O'Neil B, Welner S, LASER Analytica, Montreal, QC, Canada
- PDB95 X1 pgA69 INFO-DIABETIC APPROACH FROM CELLULAR PHONE TEXT MASSAGING CAN MINIMIZE THE COMPLEXITIES IN DIABETIC PATIENT CARE**
Kumar N¹, Gupta BK¹, Dixit VK², Pathak P³, Sharma VP⁴,¹SRM University, Barabanki, India, ²Maulana Azad Medical College, New Delhi, India, ³SGPG Institute of Medical Sciences, Lucknow, India, ⁴CSIR-Indian Institute of Toxicology Research, Lucknow, India
- PDB96 X2 pgA69 FINANCING A CURE FOR DIABETES IN A MULTI-PAYER ENVIRONMENT**
Basu A¹, Kamal-Bahl S², Subedi P³,¹University of Washington, Seattle, WA, USA, ²Pfizer, Philadelphia, PA, USA, ³Pfizer, New York, NY, USA
- PDB97 X3 pgA70 BENEFITS OF BREASTFEEDING ON DEVELOPMENT OF DIABETES MELLITUS, IN WOMEN WITH HISTORY OF GESTATIONAL DIABETES MELLITUS USING THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY**
Urs SS¹, Chandwani S²,¹ICON plc, Morristown, NJ, USA, ²Rutgers School of Public Health, Piscataway, NJ, USA
- PDB98 X4 pgA70 ASSESSMENT OF A FRENCH ENDOCRINOLOGIST ELECTRONIC MEDICAL RECORD DATABASE FOR USE IN OBSERVATIONAL STUDIES**
Hellard C, Jouaville SL, Pilet S, Meihoc A, Cedemim Strategic Data, Boulogne-Billancourt, France
- PDB99 X5 pgA70 PHYSICIAN REPORTED REASONS FOR DISCONTINUING OR DOWN-TITRATING SULFONYLUREAS IN TYPE 2 DIABETES PATIENTS**
Laires P¹, Kurtyka K¹, Witt EA², Qiu Y¹, Yu S¹, Iglay K¹,¹Merck & Co., Inc., Kenilworth, NJ, USA, ²Kantar Health, Princeton, NJ, USA
- PDB100 X6 pgA70 USE OF HEDIS A1C TARGETS IN CHARACTERIZING TREATMENT GOALS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING BASAL INSULIN**
Oster G¹, Moen D², Yang T³, Dalal M³, Kazemi M³, Sung JC³, Traylor L³, Sullivan SD⁴,¹Policy Analysis Inc., Brookline, MA, USA, ²MoenMDConsulting, St Paul, MN, USA, ³Sanofi US, Inc., Bridgewater, NJ, USA, ⁴University of Washington School of Pharmacy, Seattle, WA, USA
- PDB101 X7 pgA70 EFFECT OF DIABETES EDUCATION PROGRAM ON TYPE 2 DIABETES**
Younis M, Jackson State University, New Orleans, LA, USA
- PDB102 X8 pgA70 CHANGES IN BASELINE COMORBIDITIES, MEDICATIONS AND HEALTHCARE COSTS FOR A POPULATION OF PATIENTS WITH NEW-ONSET TYPE 2 DIABETES (T2D) IN 2007 COMPARED WITH 2012**
Weng W, Liang M, Kimball E, Hobbs T, Kong S, Bouchard J, Sakurada B, Novo Nordisk, Inc., Plainsboro, NJ, USA

RESEARCH POSTER PRESENTATIONS FLOOR PLAN



Looking for poster presentations online?

The **ISPOR Scientific Presentations Database** is a searchable database of over 31,500 research papers presented at ISPOR meetings since 1998. The database is searchable by disease, topic, meeting, key word and author. To access the database, go to www.ispor.org and click the purple "Scientific Presentations" tab.

ISPOR



Scientific Presentations Database

